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ABSTRACT 
PATIENT ACTIVATION AND MEDICATION ADHERENCE AFTER 
PHARMACOGENETIC CARE IN A CARE COORDINATION POPULATION 
JULIE KITTELSRUD 
2016 
Objective.  The purpose of the study is to compare the outcomes of patient activation 
before and after pharmacogenetic care in a coordinated care population.  The process of 
pharmacogenetic care includes the patient’s acknowledgment of medication changes 
which are based on their genetic profile.  This study will be framed by Dorothea Orem’s 
Self-Care Theory and Davies and Conley’s framework of genetic influences in 
prescribing anti psychotropic therapy.   
Background.  Understanding patient’s behavioral reactions to pharmacogenetic care in 
terms of patient activation is important to understanding patient’s health outcomes.  No 
published studies were identified in literature reviews conducted by this author which 
related to patient activation and pharmacogenetic care.  There were no published studies 
found by the author using either, or both of, Dorothea Orem’s Self-Care Theory or 
Davies and Conley’s framework. 
Methods.  This dissertation study is designed as part of a larger study nicknamed “PGX-
TIME”.  The study is a longitudinal, utilizing one-group, repeated measure design.  
Participants will complete the Patient Activation Measure-Mental health (PAM-MH) 
before and after having pharmacogenetic testing (PGX).  Medication recommendations 
will be provided to the primary care provider based on current medications and genetic 
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testing results.  Standard of care in South Dakota requires patient involvement and 
communications regarding genetic testing.  This study requires a patient’s 
acknowledgment that their medications are remaining the same or being modified based 
on pharmacogenetic testing results.  Additional information will be collected regarding 
the number of chronic conditions, the number of mental health conditions, the number of 
medications utilized, coordinated care tier level and number of genetic pathways 
affected.  A theoretical model was developed based on literature review, Orem’s model, 
Davies and Conley’s framework, to understand direct and indirect variable relationships.   
Results.  This study was stopped in January of 2016.  Therefore, no study results are 
presented in this dissertation.  Chapter one and two describe this study while chapter 
three describes the reason the study was stopped and how the study changed.  Chapter 
four presents study results, and Chapter Five includes the discussion.   
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  CHAPTER 1 
 Introduction 
Phenomenon of Interest 
   Mental illness is a common and significant co-morbid condition to other health-
related problems such as diabetes (Trief et al., 2014), cardiovascular disease (Sin, Yaffe, 
& Whooley, 2015), and obesity (Stanley, Laugharne, Addis, & Sherwood, 2013).  The 
combination of chronic disease associated with mental health diagnoses cost the U.S.  
healthcare system over $300 billion dollars in 2002, and about $210 billion of this is 
related to work absenteeism costs due to worker impairment.  Reeves et. al. (2011) 
found that in South Dakota approximately three days per month are used for mental 
health days indicating loss of work time (Reeves et al., 2011).  Many studies have 
evaluated the best way to care for patients with depression through primary care and 
psychiatric care including a more recent large-scale study titled the Sequenced 
Treatment Alternatives to Relieve Depression (Ben-Zeev et al., 2012; Smith, Easter, 
Pollock, Pope, & Wisdom, 2013; Steigman et al., 2014; Tosh, Clifton, Xia, & White, 
2014; Wisniewski et al., 2004) 
 Patient activation is one’s knowledge, skills and ability to navigate the health 
care system (Hibbard, Sockard, Mahoney, & Tusler, 2004).  Patient activation is also 
closely related to health outcomes in persons with chronic illness and mental health 
diagnoses, and authors report that those who have higher activation levels have 
improved mental health outcomes even a year later (Sacks, Greene, Hibbard, & Overton, 
2014).  Another measure of patient activation is medication adherence (Hibbard, et al., 
2004).   
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Evidence has demonstrated that medication adherence in chronic mental illness 
is poor and that medication non-adherence increases the incidence of re-hospitalization 
along with worsening patient outcomes (Mosen et al., 2007; Remmers et al., 2009).  
Medication management of mental illness most often includes more than one medication 
over long periods of time (Blaschke, Osterberg, Vrijens, & Urquhart, 2012).  A German 
study by Stieffenhofer and Hiemke (2010) indicated that medication side effects, which 
occur because of personal enzymatic pathways associated with one’s genetic make-up, 
may play a role in discontinuation of medications.  Hall-Flavin et al. (2013) note that 
pharmacogenetic guidance in medication selection reduced symptoms and improved 
clinical outcomes for patients.  Pharmacogenomics (PGX) is the study of genetics as 
they relate to the cytochrome P450 (CYP) enzymatic metabolism of medications in the 
liver (Zhou, Liu, & Chowbay, 2009).  Pharmacogenetic testing in recent years has been 
reported to decrease side effects which may contribute to reducing medication non-
adherence (Hall-Flavin et al., 2013; Mrazek, 2010b).  Currently, there are no identified 
published studies that evaluate the effect pharmacogenetic testing has on patient 
activation, and one published study related to medication adherence (Fagerness et al., 
2014).  There is a growing body of evidence regarding improvement of patient outcomes 
related to positive changes in patient activation (Sacks, et al., 2014; Sacks, Greene, 
Hibbard, Overton, 2014)(R. M. Sacks, J. Greene, J. H. Hibbard, & V. Overton, 2014).  
Additionally, studies address the potential of pharmacogenetic testing to impact 
medication adherence because of the reduction of side effects (Hall-Flavin et al., 2013; 
Hall-Flavin et al., 2012).  It is the intent of this study to evaluate patient activation 
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before and after pharmacogenetic testing has been performed to confirm or adjust patient 
medications. 
Background 
 Few published research studies have focused on the effect genetic testing, such as 
pharmacogenetic testing, has on patient behavior (Sacks et al., 2014; Sacks et al, 2014) 
patient behavior.  The process of conducting genetic testing requires a specific process be 
followed in South Dakota, and standard of care requires open communications between 
providers and patients.  As the standard of care, the provider will discuss the testing and 
any medication changes based on the pharmacogenetic testing results with the patient's 
acknowledgment of the process (Appendix A).  This process will be considered 
pharmacogenetic care for this study. 
             There are currently no published studies identified at this time, which examine 
patient activation and pharmacogenetic care.  Patient activation improves not only 
medication adherence but also health outcomes.  When a patient is activated or engaged 
in their healthcare, there is increased motivation in health-related behaviors.  Some of 
these include; improved diet, exercise and obtaining preventative screening tests 
(Hibbard et al., 2004).  Several studies have reported that high patient activation 
measures correlate to better health outcomes in biometric indicators of health such as 
blood pressures, Hemoglobin A1C (HgA1C)  levels, cholesterol levels, and body mass 
index  (Hibbard & Greene, 2013; Rogvi, Tapager, Almdal, Schiotz, & Willaing, 2012; R. 
Sacks et al., 2014; Skolasky, Mackenzie, Wegener, & Riley, 2011). 
 A component of the measurement of patient activation is the outcome of 
medication adherence.  Haga and LaPointe (2013) have speculated that the act of 
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pharmacogenetic testing will increase a patient’s medication adherence.  However, only 
one published study was identified by Fagerness et al. (2014) which examined pharmacy 
refill data for those patients who received pharmacogenetic testing.  This study reported 
higher medication adherence in those patients who had genetic testing over those who did 
not have testing.  Furthermore, Haga and LaPointe (2013) described additional factors 
that may relate to other positive impacts of pharmacogenetic testing, such as less need for 
medication dosing adjustments, fewer changes in medications, fewer side effects, 
opening communication between provider, and patient and the potential of less time to 
therapeutic outcomes.  These factors may contribute to medication adherence after 
pharmacogenetic testing and, therefore, increase patient activation.   
 Some studies have addressed improved medication adherence in patients who 
have had genetic risk testing (Charland et al., 2014; Grant et al., 2009).  Grant et al. 
(2009) reported that participants with and without type 2 diabetes indicated in a self-
report survey that they would be more likely to have higher motivation to change their 
lifestyle if they had a ‘high risk’ gene for diabetes.  Moreover, participants described that 
they would be ‘much more motivated’ to be compliant with their medications (Grant et 
al., 2009).  Additionally, Charland et al. (2014) reports increased adherence to statin 
medications after testing the risk gene, KIF6, which indicates increased risk for 
Congestive Heart Disease (CHD).  One recent study evaluating retrospective health 
claims refill data, noted that those participants who had pharmacogenetic testing were 
more adherent to their medication (Fagerness et al., 2014).   
Patient activation has been noted to be low in patients with mental health 
disorders (Gunn et al., 2012; R. Sacks et al., 2014; Whooley et al., 2008).  As defined by 
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Hibbard (2008) activation refers to how engaged one is in managing his or her healthcare 
and this can change over time.  It follows that if pharmacogenetics may improve a 
patient’s engagement in their healthcare, medication adherence may also improve.  The 
amount of activation a patient may have in his or her healthcare is variable based on 
patient interest, skills, the capacity to understand and diagnoses (Von Korff, Gruman, 
Schaefer, Curry, & Wagner, 1997).  To date, there were no studies identified in this 
author’s literature review which examined the patient response to pharmacogenetic 
testing as a relationship to patient activation. 
Problem statement 
 Pharmacogenetics is an innovation that is becoming more widely accepted as a 
clinical application of genetics, and its implementation has shown benefit with 
psychiatric medications in mental health (Hall-Flavin et al., 2013; Mrazek, 2010a; 
Mrazek & Lerman, 2011).  Within the context of clinical implementation, 
pharmacogenetic (PGX) testing may have indirect effects that may benefit patient 
behavior, such as increasing medication adherence (Charland et al., 2014).  It follows 
that if there is evidence of increasing medication adherence, there could also be an 
increase in patient activation.  However, a study utilizing patient activation has not been 
conducted in mental health and chronic illness population in association with medication 
adjustments based on pharmacogenetic testing.  
Purpose of the Study 
 The purpose of the study was to compare the outcome of patient activation 
before and after medication recommendations have been made utilizing 
pharmacogenetic testing information in a chronic illness and mental health population.  
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Care coordination patients had access to pharmacogenetic care.  Based on 
pharmacogenetic testing and a pharmacist’s review of current medications, 
recommendations for medication and or dosage adjustments were made.  The provider 
was assigned to oversee the patient along with the care coordinator who provided the 
information to the patient regarding their completed pharmacogenomic testing results.  
Also, the coordinator and or the provider communicated that their medications were 
being adjusted based on the genetic test.  The patient acknowledged that their 
medication is being changed or not changed based their personal genetic profile.  Other 
variables that were collected for a primary study (PGX-TIME) were also incorporated 
into the analysis for the dissertation such as, demographic information, number of CYP 
enzyme pathways that are clinically affected by decreased or increased enzyme activity, 
number of chronic conditions, the number of prescription medications and the number of 
mental health conditions.  
Research Questions and Hypotheses 
1. Does patient activation improve from admission to one month of care 
coordination in a population of patients with chronic conditions and mental 
illness? 
a. Patients with chronic conditions and mental health will improve patient 
activation scores after beginning care coordination. 
b. H0 = PAT1 = PAT2 
c. H1 =  PAT1 < PAT2 
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2. Does patient activation improve after pharmacogenetic care in patients with 
chronic illness and mental health diagnoses who are participating in a care 
coordination population? 
a. Patient activation scores will improve from time 2 to time 3 after 
pharmacogenetic care.  
b. H0 = PAT2 = PAT3 
c.  H1 = PAt2 < PAt3 
3. Does patient activation improve after patients with chronic illness and mental 
health enter care coordination and have pharmacogenetic care? 
a. Patient activation scores will improve from time 1 to time 3 after entry to 
care coordination and pharmacogenetic care. 
b. H0 = PAT1 = PAT3 
c.  H1 = PAT1 < PAT3 
4. Do the classifications of TIER level, number of medications, number of 
chronic illnesses, and number of affected genes, affect the level of change in 
patient activation in a care coordination population?  
Nursing Theory 
 Dorothea Orem’s Theory of Self-Care Deficit includes three midrange theories, 
which together attempt to define nursing practice and guide nursing curriculum (Orem, 
2001).  The three theories include; Theory of Self-Care, Theory of Self-Care Deficit, and 
Theory of Nursing Systems (Orem, 2001; Parker & Smith, 2010).  This study will 
incorporate the Theory of Self-Care as measured by the PAM-MH and MMAS-8.   
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  Three central concepts including; “self-care, self-care agency and therapeutic 
self-care demand” make up self-care theory (Denyes, Orem, & Bekel, 2001; Nursing 
Development Conference Group, 1979; Orem, 1987, p. 70)  Self-Care is a learned, 
voluntary and deliberate activity to maintain wellness and health (Nursing Development 
Conference Group, 1979; Orem, Taylor, & Renpenning, 1995).  Patient activation 
(PAM-MH) is evidence of self-care in its measures of self-capability, learned knowledge 
and beliefs of health care and medication use (Green et al., 2010; Hibbard et al., 2004).  
Additionally, medication adherence, as measured by the MMAS-8, is evidence of self-
care and self-care requisites (Morisky, Ang, Krousel-Wood, & Ward, 2008).   
 Self-care agency is the power and ability to care for the self, and, therefore, 
nursing agency is the capability, knowledge and insight into the patients needs as self-
care agents with deficits (Renpenning & Taylor, 2003).  Motivation and motives are the 
basis for self-care agency and are followed by the health behavior actions.  This study 
evaluated self-care agency as a component of patient activation, and medication 
adherence as a part of self-care requisites. 
Theoretical Framework 
 Davies, Conley and Puskar (2010) produced a theoretical framework targeted to 
the practicing clinician.  It was developed by evaluating challenges that clinicians face 
when choosing antipsychotic medications.  The challenges are that a provider must be 
aware of, and knowledgeable regarding pharmacology of drugs, molecular genetics of 
drug targets, and genetics of drug metabolism to prescribe medications (Davies, Conley, 
& Puskar, 2010).  Components of the framework related to patients include; family and 
9 
  
patient education, medication planning, medication monitoring, and patient outcomes 
(Davies et al., 2010).   
Definition of terms  
 Mental health.  Mental health conditions most commonly seen by the care 
coordination team includes, depression, anxiety, personality disorders, post-traumatic-
stress disorder, bipolar-disease, and schizophrenia.  However, this list may vary based 
on the population of the primary study, PGX-TIME.    
 Serious Mental Illness (SMI).  SMI is when mental health disorders are serious 
enough to impact a patient’s activities of daily living (NIMH, 2012).  The population for 
this study has mental health conditions in the category of serious mental illness. 
 Patient Activation.  An activated patient is a patient who has the knowledge, 
skills and ability to navigate the health care system to engage in personal self-care to 
maintain health and wellbeing (Hibbard et al., 2004).  
 Medication Adherence.  Medication adherence is the ability and willingness to 
take medications as they are prescribed by a provider on a continuing basis to maintain 
health (Morisky et al., 2008; Morisky & DiMatteo, 2011). 
 Pharmacogenetics.  Pharmacogenetics (PGX) is the study of genetics as they 
are related to the cytochrome P450 (CYP) enzymatic metabolism of medications, 
transporter and receptor genes in the liver (Zhou et al., 2009).  
 Pharmacogenetic care.  Pharmacogenetic care refers to the provider and patient 
interaction that surrounds the process of testing.  These elements include the patient’s 
informed consent to perform the genetic testing, a provider order, a return of genetic 
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report with information regarding pharmacist recommendations and the patient’s 
acknowledgment that medication changes were made based on their genetic profile.   
Significance of the Study 
 This study is significant to patient outcomes, providers, and health systems.  
Patients who have pharmacogenetic testing and show an improvement in patient 
activation will have better health outcomes such as improved mental health conditions, 
decreased depression, decreases in symptoms and side effects and overall, improved 
quality of life.  Potentially, there may be a benefit to both the patient and insurance 
providers related to costs.  For example, when one is started on the correct medication 
because the provider understands not only the clinical picture but also the genetic 
snapshot of a patient’s drug metabolism, the patient will have improvement in their 
health conditions.  Moreover, the patient may experience fewer side effects without the 
expense of frequent changes in medications or additional medications to control these 
side effects.   
 In consideration of providers and other professions working with patients, 
opening communication between the provider and patient because of pharmacogenetic 
testing may increase patient activation and medication adherence.  Furthermore, increases 
in activation and medication adherence may decrease the number of suicides, promote 
patient’s active participation in preventative medicine, decrease missed clinic visits and 
promote the intentional and appropriate use of resources.  This study is a broad-reaching 
study when considering the potential impact on patient’s health outcomes, costs to the 
patient and hospital systems, and availability of new prescribing resources for the 
provider in an ever-changing and complex system of pharmaceuticals. 
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CHAPTER 2 
 Literature review 
Introduction 
 Chapter two reviews the current literature as it relates to the primary points of 
interest to this study.  This study compared the outcome of patient activation before and 
after medication recommendations had been made utilizing pharmacogenetic testing in a 
chronic illness and mental health population.  Therefore, current literature related to the 
following topics was critically evaluated; (a) prevalence and trends in mental health care; 
(b) patient activation, the concept itself and its relationship to chronic illness, diabetes, 
hypertension, and mental health; (c) medication adherence; (d) pharmacogenetics and 
behavioral outcomes; and (e) gaps in the literature related to pharmacogenetics and 
behavioral outcomes in the mental health population. 
Prevalence and Trends in Mental Health 
 Serious mental illness (SMI) as defined by the National Institute of Mental Health 
(NIMH), as a diagnosis of mental illness in the 4th edition of the Diagnostic and 
Statistical Manual of Mental Disorders (DSM-IV)  seriously impacts a patient’s daily life 
(NIMH, 2012).  SMI accounts for 9.4 million people in the United States (US) alone, 
which is about 4.1 percent of the US population (NIMH, 2012).  The gender most 
affected with SMI are females (4.9 %), and the age ranges between  26-49 years old 
(5.2%) (NIMH, 2012).  Also, Medicaid use within this population is significant at about 
8.5% of patients with SMI (NIMH, 2012).  Many patients with SMI do not seek out 
mental health services.  However,  a survey in 2008 reports that 40% of patients with 
mental health conditions first utilize primary care (Center for Disease Control, 2008).  
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Significant physical conditions are associated with mental illness and include diabetes 
(Trief et al., 2014), cardiovascular disease (Sin et al., 2015), and obesity (Stanley et al., 
2013).  The combination of mental illness and chronic conditions affect the ability of 
patients to care for themselves.  Additionally, poor outcomes, such as increased 
depression, and increased suicide are associated with this combination of disorders 
(Salyers, Matthias, Sidenbender, & Green, 2013; Trief et al., 2014).  
 There are many issues leading to under-recognition and insufficient treatment of 
psychiatric illness in the primary care setting (Eisenberg, 1992; Gallo & Coyne, 2000; 
Williams, 1998).  One such issue is a general reluctance due to stigma, of patients to 
report mental illnesses and instead, patients seek primary care services for somatic 
complaints (Wells et al., 2000; Williams, 1998).  The ability to seek appropriate care, as 
part of patient activation, is an important step in self-care management (Chen, Mortensen, 
& Bloodworth, 2014; Orem, 2001).  Katon et al. (1997) estimate that as high as 80% of 
patients with depression seek out primary care services for somatic complaints without 
mention of depressive symptoms to the primary provider.  Another issue is finding the 
correct treatment for the patient.  In the 1990’s the Food and Drug Administration (FDA) 
approved Selective Serotonin Receptor Inhibitors (SSRI’s), which increased the number 
of prescriptions through primary care services.  This increase was related to the decreased 
risk of side effects and the decreased need for follow-up (Cutler, 2001; Cutler & 
McClellan, 2001). 
  Paton, Esop, Young, and Taylor (2004) conducted a clinic review of recorded 
lipids and Body Mass Index (BMI) in schizophrenic patient charts, and reported that 
these data were not found in the majority of schizophrenic patient charts reviewed.  
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Similarly, Roberts, Roalfe, Wilson, and Lester (2007) examined charts of schizophrenia 
patients who use primary care and found that an inequality of care exists compared to 
other patients reporting that schizophrenia patients were half as likely to have blood 
pressure and cholesterol levels checked than asthma patients.  However, Tosh et al. 
(2014) completed an extensive review of the literature and revealed that overall the 
literature does not report clear inequalities between schizophrenia patients and other 
patients.  There is inconclusive, yet potentially negative evidence, in the literature review 
regarding the quality of care, and access to care that patients with mental health 
conditions experience.   
  Muir-Cochran (2006) report that patients with mental health conditions have 
increased challenges with negotiating the medical system and therefore, are less activated 
in their health care.  It is documented that patients with mental illness are less engaged in 
their health care than those without mental illness (Muir-Cochrane, 2006).  Overall, the 
high prevalence of complicated patients with mental health disorders who are being cared 
for in primary practice illustrates a clear picture of the unmet needs of this population. 
Patient Activation Literature Review  
 The literature was searched using the keyword in quotations, “patient activation”, 
which yielded 944 articles on EBSCOhost choosing all databases.  Limiting the scope to 
the full article, and peer-reviewed articles, a total of 342 articles were available.  When 
the scope was narrowed to “patient activation” and “chronic illness”, 144 articles were 
noted as available.  These abstracts were reviewed for relevance to the study.  Articles 
were also obtained from the PAM website www.insigniahealth.com to total 71 articles 
evaluating patient activation in various chronic disease states.  A discussion of the 
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concept development related to patient activation and a review of literature related to 
chronic conditions follows.   
Patient Activation 
 The socially driven underpinnings of the concept of “patient activation” are 
directed at two main health initiatives.  The first is the transition of reimbursement 
towards patient-centered containment of costs with improving health outcomes or 
consumer-driven insurance plans (Hibbard et al., 2004).  The second is Bodenheimer, 
Lorig, Holman, and Grumbach (2002) development of the Chronic Illness Care Model 
(Hibbard et al., 2004).   
 Health plan impact.  Consumer-driven health plans (CDHP) was a cutting-edge 
topic debated at the 6th Annual World Health Care Congress in 2009 ("Making the Shift 
to Consumer-Directed Health Care Remains a Challenge for Many," 2009).  At the heart 
of the discussions were issues related to empowerment of the patient to become engaged 
in their health plan by allowing incentives from insurance companies ("Making the Shift 
to Consumer-Directed Health Care Remains a Challenge for Many," 2009).  The term 
“consumer-driven” is a reference to the design of insurance reimbursement programs that 
puts the patient at the center of the decision process for their personal care (Gabel, Lo 
Sasso, & Rice, 2002, p. W395).  
  A study conducted by Loeppke et al. (2008) evaluated a health enhancement 
program following a risk assessment on employees’ health.  The health enhancement 
program encouraged participants to make healthy choices and participants were able to 
earn $300 off of their insurance premiums.  The next year of health screenings showed an 
improvement in health outcomes (Loeppke et al., 2008).  Similarly,  HRA plan members, 
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who engaged in better health practices reportedly used less asthma, cardiac, and 
cholesterol medications (Song, Levin, & Gartner, 2010).  Wilson et al. (2008) researched 
utilization differences between those enrolled in a CDHP and a comprehensive major 
medical (CMM) plan.  The findings show no differences in utilization of services in the 
areas that were beyond the patient’s control such as inpatient hospital stays.  However, 
there was a significant reduction in the use of preventative services and emergency room 
visits for those with CDHP’s (Wilson et al., 2008).  An evaluation of CDHP members 
reported that they followed healthier self-care behaviors than non-memebers.  For 
example, fewer members engaged in smoking, more members exercised, and more 
obtained preventative exams (Fronstin, 2012).  This example illustrates that a high 
engagement in one’s self-care behaviors reportedly improves health outcomes.   
 Chronic illness care model impact.  Edward H Wagner, MD developed the 
Chronic Illness Care Model (CICM) which is based on six elements that when 
incorporated by the patient and primary provider increase the collaboration and 
effectiveness of the healthcare system (Bodenheimer, Wagner, & Grumbach, 2002).  
These six pillars are similar to the philosophical underpinnings of patient activation and 
include; support of self-management, clinical information structure, redesign of the 
delivery system, decisional support, health care organization, and community resources 
(Bodenheimer, Wagner, et al., 2002). 
 Philosophical underpinnings of Patient Activation.  Hibbard et al. (2004) 
conducted focus groups to understand and conceptualize “activation” and conducted a 
literature review, searching terms related to the concept.  This review identified six 
domains which were utilized in focus groups and include; (a) self-management of 
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symptoms; (b) engagement in health maintenance activities; (c) conduct activities that 
maintain health; (d) participation in treatment decisions; (e) work with caregivers and 
providers; (f) understand the health system operations and ability to navigate the system 
(Hibbard et al., 2004).  These six findings directed the focus group discussions.   
 An expert panel and patient panel were queried regarding patient’s “knowledge, 
beliefs, and skill needed to manage and live with a chronic condition” as they relate to 
each of the six identified areas found in the literature (Hibbard et al., 2004, p. 1008). The 
expert panel identified that the patient is important in the areas of self-management, 
collaborating with the provider, and maintaining function.  Additionally, they concluded 
that knowledge and skills are needed to self-manage, and maintain functional health.  
Alternatively, they described that knowledge was not needed for collaboration with a 
provider, but skills were valuable in collaborating with a provider (Hibbard et al., 2004).  
Overall, activated patients believe in, and know how to, self-manage their chronic 
conditions use their collaborative skills and have the ability to navigate the system. 
 Patient activation and disease states.  Five studies identified, have provided 
evidence that highly activated patients have better health behaviors such as, being 
exercisers, non-smokers, and those who follow-up with preventative exams (Hibbard, 
Mahoney, Stockard, & Tusler, 2005; Hibbard et al., 2004; Hibbard, Mahoney, Stock, & 
Tusler, 2007).  Overall, patient activation has been evaluated in many settings, and health 
states representing chronic illness (Alexander, Hearld, Mittler, & Harvey, 2012; Kinney, 
Lemon, Person, Pagoto, & Saczynski, 2015), diabetes (Begum, Donald, Ozolins, & 
Dower, 2011; Rask et al., 2009; Woodard, Landrum, Amspoker, Ramsey, & Naik, 2014), 
hypertension (Ryvicker, Feldman, Chiu, & Gerber, 2013; Thiboutot et al., 2013), 
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orthopedic surgery (Skolasky, Mackenzie, Wegener, & Riley, 2008), heart failure 
(Gardetto, 2014; Shively et al., 2013), Inflammatory bowel disease (Munson, Wallston, 
Dittus, Speroff, & Roumie, 2009), and multiple sclerosis (Goodworth et al., 2014; Packer 
et al., 2015; Stepleman et al., 2010). 
 Patient activation and chronic illness.  Provider contact and communication 
contributes to higher activation levels and is exemplified by the information that patients 
with higher activation levels perceive a good relationship with their providers and see 
that their treatment plans were fairly executed (Alexander et al., 2012).  Additionally, 
Wong, Peterson, and Black (2011) found that the more time spent with a provider, the 
higher the activation level became.  Overall, diabetic and cardiovascular disease patients 
with higher activation decreased the number of visits to their provider, potentially 
indicating better self-management (Donald et al., 2011). 
 Information on patient activation and patient outcomes are new and rapidly 
growing with 27 articles published since 2007 relating to patient outcomes as they relate 
to patient activation levels.  It is important to understand how having a high, or low 
activation level relates to patient outcomes.  For example, those with low activation 
levels were found to have a higher risk for re-hospitalization and risk for higher numbers 
of emergency room visits (Kinney et al., 2015).  When  Remmers et al. (2009) conducted 
a secondary analysis on data collected for a previous study by Mosen et al. (2007) and 
collected additional information for each participant, they found that patient activation is 
a malleable trait that declines over time.  These authors suggested that this change is due 
to a decreases in perceived health, and a reduction in ability to care for themselves 
(Remmers et al., 2009).  When health outcomes were assessed in the four areas of 
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prevention, unhealthy behaviors, clinical indicators and costly utilization, it was found 
that those with high activation had fewer emergency room visits and lower systolic blood 
pressure.  However when comparing those with high activation to those with lower 
activation levels, triglycerides, Low-Density Lipoprotein  (LDL), HgA1C levels and 
diastolic blood pressures did not differ (Greene & Hibbard, 2012).  Also, patients who 
have low patient activation along with multiple chronic illnesses who participate in care 
coordination tended to self-report problems with care coordination (Maeng, Martsolf, 
Scanlon, & Christianson, 2012).   
 Patient activation and diabetes.  Chronic conditions like diabetes require daily 
monitoring plus the skill and knowledge to self-manage (Rask et al., 2009; Remmers et 
al., 2009).  Patient activation on the topic of diabetes care evaluated the health outcomes 
of self-management, and associations with HgA1C.  Rask et al. (2009) studied 287 
African Americans, who were primarily female and uninsured, finding that those more 
activated patients performed frequent foot exams, had eye exams annually, and higher 
self-management skills.  However, there was no evidence that patient activation had any 
relationship to HgA1C levels (Rask et al., 2009).  On the other hand, Remmers et al. 
(2009) reflected that those who had higher PAM levels had lower HgA1C levels and 
decreased LDL levels.  Moreover, the converse was true as well, indicating a predictive 
nature of the PAM to health outcome measures of HgA1C (Rask et al., 2009).  In 
contrast, Mayberry et al. (2010) concluded that only those with the highest level of 
activation as scored by the PAM would see a decrease in HgA1C levels. These studies 
indicate that patient activation has an impact on diabetes self-care, but that there may be 
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other issues influencing HgA1C levels that are more complex than what patient activation 
may measure.   
 Intervention studies have indicated that there are several methods to improve 
activation and, therefore, diabetes self-care behaviors and outcomes.  Bolen et al. (2014) 
reviewed the literature and conducted a meta-analysis illustrating the effectiveness 
though mild, of patient activation interventions.  Social support and participatory decision 
making as interventions were positively related to higher patient activation scores on the 
PAM and better HgA1C levels (Parchman, Zeber, & Palmer, 2010; Schiotz, Bogelund, 
Almdal, Jensen, & Willaing, 2012).  It has been previously shown that by improving 
activation levels, patient health outcomes and costs improve (Greene, Hibbard, Sacks, 
Overton, & Parrotta, 2015).  Additionally, online interventions and educational programs 
have been reported as effective to improve diabetes-related outcomes and patient 
activation (Lorig, 1996; Lorig et al., 2010). 
 Patient activation and hypertension.  A study using interventions to improve 
patient activation in a primarily black, hypertensive population, did not show positive 
outcomes for the intervention but concluded that those with low activation improved 
control better than those with higher activation scores (Ryvicker et al., 2013).  In the 
study by Ryvicker et. al. (2013), it was reported that those participants who had higher 
activation levels, were younger aged, had lower blood pressures, higher health literacy, 
higher education levels, fewer medications, and diabetes.  Other studies also have had 
difficulty finding patient activation interventions to be successful in reducing blood 
pressures, having similar findings to the study by Ryvicker et al. (2013) with patient 
activation (Thiboutot et al., 2013; Wagner et al., 2012). 
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 Patient activation and other illnesses.  Other diagnoses, such as heart failure 
(Gardetto, 2014; Shively et al., 2013), inflammatory bowel disease (Munson et al., 2009), 
multiple sclerosis (Goodworth et al., 2014; Packer et al., 2015; Stepleman et al., 2010) 
and orthopedic surgery (Skolasky, Mackenzie, Riley, & Wegener, 2009; Skolasky, 
Maggard, Li, Riley, & Wegener, 2015), have been also been studied in association to 
patient activation .  These conditions may be similar to the population in chronic care 
coordination who will participate in this study. 
 Gardetto (2014) evaluated patient activation in patients who had heart failure 
attempting to link characteristics such as, confidence and emotional status, to activation 
in those with chronic conditions plus heart failure.  This study found a mediating 
relationship between increased confidence and higher scores of activation, and partial 
mediation of self-management behaviors (Gardetto, 2014).  Those patients who were 
more activated in their care had better heart failure outcomes, such as improved New 
York Heart Association scores, functional capacity, and anxiety, than those who were 
less activated (Gardetto, 2014). Shively et al. (2013) conducted a randomized controlled 
study of an intervention to improve patient activation in heart failure patients and found 
similar results to Gardetto (2015).  The conclusion in both studies was that those patients 
who were more activated had better health outcomes with their heart failure management 
(Gardetto, 2014; Shively et al., 2013).   
 Patient activation and mental health.  The literature searches for patient 
activation and mental health turned up one article for PAM-MH, related to the tool 
development.  Subsequent searches revealed that mental health conditions tended to be 
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included under the general term of “patient activation” and overall 14 studies were 
evaluated which were identified on a reference list from www.insignia.com.   
 Patients with mental illness are noted to have reduced motivations to seek medical 
care, are less apt to follow through with care, and less likely to be involved in decisions 
related to their care (Muir-Cochrane, 2006).  There is substantial evidence that those with 
SMI have significant difficulties following through with their routine health care and 
following healthy behaviors.  For example, two studies noted that mortality rates are 
higher in this population than those without mental illness (Brown, Birtwistle, Roe, & 
Thompson, 1999; Saha, Chant, & McGrath, 2007).  Patients suffering from SMI have 
higher obesity rates (Allison et al., 1999; Green, Patel, Goisman, Allison, & Blackburn, 
2000), lower activity levels (Daumit et al., 2005), higher cardiovascular complications 
and high smoking rates (Goff et al., 2005).   
 An overall evaluation of patient activation in mental illness shows that activation 
levels are low in a mental health population when depression is noted to be high, and 
quality of life is low, according to the Short Form Quality of Life (SF-12) and Patient 
Health Questionnaire (PHQ-9), a depression scale (Magnezi, Glasser, Shalev, Sheiber, & 
Reuveni, 2014).  The converse, high activation levels were associated with low levels of 
depression and high levels of quality of life, was also shown in this study (Magnezi et al., 
2014).  Moreover, a study by Sacks et al. (2014) indicates that activated patients have 
better long-term outcomes than less activated patients.  One-year follow-up of patients 
who were more highly activated indicated that they also were managing their depression 
as evidenced by higher remission rates and lower PHQ-9 scores (Sacks et al., 2014).  
Chen et al. (2014) found that activation was greater when certain contextual factors, such 
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as familiarity of provider and high levels of community resources are available.  This 
study gives evidence to the need for community resources and consistent care, which 
enhance patient activation levels (Chen et al., 2014). 
 Four studies were identified that evaluate interventions, such as increasing 
communication (Alegria et al., 2008), the use of the Health and Recovery Program  
(Druss et al., 2010),  and the use of web-based technology to increase patient activation 
(Solomon, Wagner, & Goes, 2012; Solomon, 2010).  Both communication and the use of 
a defined program had positive effects on increasing a patient’s activation total scores, 
increased attendance at follow-up appointments, but did not improve empowerment 
(Alegria et al., 2008; Druss et al., 2010).  Also, web-based technology was effective at 
changing activation levels, and recommendations were made to target specific levels of 
activation in these web-based interventions (Solomon et al., 2012; Solomon, 2010).  
When considering patient activation and its relationship to chronic illness and mental 
health diagnoses, having pharmacogenetic testing and medications prescribed based on 
these results, no published literature was found.   
Medication Adherence Literature Review 
 A search for the term “medication adherence” and “medication compliance” on 
EBSCOhost with all databases chosen, yielded 13,726 and 14,320 respective articles.  
Limiting the search to peer-reviewed scholarly articles and full articles available, the 
result was 5,791 and 5,005”.  Also, limiting the date from 2000 to 2015 only excluded 50 
articles.  When the terms “mental health” and “chronic illness” were added, the articles 
were limited to 15.  Through bibliographic references, additional articles were found 
resulting in a review of 22 articles.  Ten articles were found when the terms 
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“pharmacogenetics or pharmacogenomics” were added to the search terms of 
“medication adherence” and “medication compliance.” All of these articles were opinion 
articles, and only one study was identified in these ten articles as relevant to this 
dissertation topic.   
Medication Adherence 
 Response to medication follows a known path; one must take the medication to 
have a positive effect from medication.  Medication adherence or compliance is a 
multifaceted element within patient activation and includes a cascade of events that occur 
within the patient and between the patient and other entities, such as the physician and 
healthcare system (Dowell & Hudson, 1997).  As described by Dowell & Hudson (1997), 
medication adherence as a concept, includes the patient’s understanding and acceptance 
of their medical condition, their ability to try the medication, and their acceptance or non-
acceptance of taking the medicine.   
  Research indicates that those who accept their illness and accept their 
medications are accountable (Dowell & Hudson, 1997).  Additionally, studies report that 
those who felt like they had more input in their medications, thus more engagement in,  
had higher medication adherence rates (De Las Cuevas, Penate, & de Rivera, 2014).  One 
qualitative study evaluating low-income, chronically ill participants, describe that 
medication compliance fell when patients did not have the feeling of sharing the decision 
with their provider (Mishra, Gioia, Childress, Barnet, & Webster, 2011).  When a person 
feels there is little choice to take medication, psychological reactance occurs.  This 
psychological reactance can be an important factor in medication adherence of 
antidepressants (De Las Cuevas, Penate, & Sanz, 2014).  When self-efficacy was 
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evaluated, there was no effect on medication adherence (De Las Cuevas, Penate, & de 
Rivera, 2014).  Interestingly, education given to patients regarding the medication and its 
use was also ineffective at increasing medication adherence (Gray, Wykes, & Gournay, 
2002). 
 Medication non-adherence is significant in mental health because it affects patient 
outcomes, health care costs and increases depression relapses (Cantrell, Eaddy, Shah, 
Regan, & Sokol, 2006; Geddes et al., 2003; Melfi et al., 1998).  Overall, those who are 
less educated, poor, and living in a rural area are less likely to be compliant especially 
with antipsychotic medications (Martin-Vazquez et al., 2011).  Furthermore, those who 
are younger, have less understanding of their illness, and were diagnosed at an early age 
with schizophrenia were less compliant (Sarath Chandra, Lokesh Kumar, Pramod Reddy, 
& Pavan Kumar Reddy, 2014).  In a study evaluating relapse in depression, three-fourths 
of those who took their medications as directed did not relapse (Geddes et al., 2003).  
Nevertheless, only half of patients who are taking antidepressants and are diagnosed with 
major depressive disorder are compliant with their medication regime after three months 
of use (Julius, Novitsky, & Dubin, 2009; Roca et al., 2011).  Similarly, patients with 
schizophrenia have a 50-60% compliance, and bipolar patients have the lowest reported 
medication adherence at only 35 % (Colom et al., 2000; Lacro, Dunn, Dolder, Leckband, 
& Jeste, 2002; Perkins, 2002).   
 In complex patients with multimorbid disease diagnoses and mental health issues, 
medication adherence becomes more complex with each additional provider (Hansen et 
al., 2014).  Hansen et al. (2014) found that the threshold of difficulty arises as soon as 
more than three providers are caring for a patient and prescribing medication.  
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Commonly, patients who are this complex have more than one provider (Parchman, 
Pugh, Noël, & Larme, 2002). 
  Provider expectations also have an impact on patient adherence and health 
outcomes as described by Byrne and Deane (2011); Byrne, Deane, and Caputi (2008).  
For instance, one study evaluated provider belief in the patient’s ability to be compliant 
indicating a relationship of low expectations by providers yielding low adherence in 
patients (Byrne et al., 2008).  Byrne and Deane (2011) later evaluated if the relationship 
between patient and provider affects medication adherence and found that a program 
aimed at understanding medications could not only foster increases in medication 
adherence but also enhance the patient-provider relationship. 
 The health care system, reimbursement, and other outside factors may also 
influence a patient’s ability to remain compliant with medications (Dowell & Hudson, 
1997).  A qualitative study conducted by Kauppi, Hätönen, Adams, and Välimäki (2015)  
in which focus groups were conducted with providers and patients, reported that 
adherence was affected by the mental health system itself, relationships of providers, how 
follow-up was carried out, and the ability to take into account a patient’s life view when 
prescribing medications.  Patients in the qualitative study stated that they would like to 
know their provider and that this would help medication adherence.  Additionally, 
patients have a learning curve associated with new medications and the language of 
healthcare (Kauppi et al., 2015). 
 Adverse effects may drastically affect medication adherence and are frequently to 
blame for patient’s discontinuation of antipsychotic medication (Demyttenaere et al., 
2001).  In depressed patients, discontinuation of treatment occurs because of side effects 
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about 23-33% of the time (Hu et al., 2004).  For example, the most common adverse 
effects reported for the antidepressant Nortriptyline are dry mouth, blurred vision, 
dizziness upon standing, and urinary symptoms, which are very similar to other 
antidepressant medications.  These contributed to medication discontinuation in the 
genome-based therapeutic drugs for depression (GENDEP) study (Uher et al., 2009).  
This study also noted that side effects occurred at the beginning of treatment and 
decreased over time (Uher et al., 2009).  
 A German study evaluated patient medication adherence and serum blood levels, 
finding inconsistencies that may be attributed to pharmacogenetic effects (Stieffenhofer 
& Hiemke, 2010).  For example, those who had genetically higher enzymatic activity, 
which is called ultra-rapid metabolism (UR), through the CYP genetics, had lower serum 
concentration of medication.  Additionally, those who were genetically poor enzymatic 
metabolizers (PM) had higher serum medication levels.  Therefore, while patient 
medication adherence may affect drug levels, pharmacogenetics may also play a role.   
 One sentinel study by Fagerness et al. (2014) evaluated insurance claims data for 
patients who had received pharmacogenetic testing and medication guidance based on the 
results of testing.  When compared to a control group of patients without genetic testing, 
the patients who received pharmacogenetic testing filed fewer insurance claims resulting 
in a $546 savings per patient over a four months’ interval.  Additionally, the patients who 
had pharmacogenetic testing had claims data indicating increased medication compliance 
when compared to the control group (Fagerness et al., 2014).  It has been recognized that 
the potential for this increased medication compliance could be related to the opening of 
communications between the provider and patient regarding medications and their 
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suitability based on genetic testing (Haga & LaPointe, 2013).  However, no identified 
studies have focused on communication, pharmacogenetics and medication adherence.  
Pharmacogenetics in clinical practice  
 ‘Pharmacogenetics,' a term coined by Friedrich Vogel in 1959, is the study of 
drugs as they relate to a person’s genetic make-up (Eichelbaum, Ingelman-Sundberg, & 
Evans, 2006; Vogel, 1959).  Specifically, pharmacogenetics refers to the interaction of 
drugs and the genetic makeup affecting the protein production in the cytochrome (CYP 
450) enzymatic pathways of the liver  (Ma, Lee, & Kuo, 2012).  Consequently, this 
affects drug metabolism by modification of enzyme activity within the pathway (Ma et 
al., 2012).  Pharmacogenetic testing is an innovative approach to finding the “right drug” 
for the “right person” (Eichelbaum et al., 2006).  
 As previously noted, open communications are required between provider and 
patient when genetic testing occurs.  This communication is set in South Dakota state law 
as of 2001 and includes appropriate informed consent from the patient regardless of study 
participation.  Standard of care when laboratory tests are ordered is that a provider 
discusses the results with the patient and how the treatment plan may change based on the 
ordered test.  This study requires documentation of acknowledgment that medications 
will be changed or confirmed based on the pharmacogenetic testing (South Dakota State 
Legislature, 2001).  
 The Pharmacogenetics Research Network (PGRN) was developed in the year 
2000 through the National Institutes of Health (NIH) and is composed of a multi-
disciplinary group established to evaluate pharmacogenomic impact on health 
(Pharmacogenetic Research Network, 2015).  It is through the PGRN that the Clinical 
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Pharmacogenetic Implementation Consortium (CPIC) has put together evidence-based 
guidelines for the use of pharmacogenetics in practice. The Dutch Pharmacogenetic 
Working group (DPGW) is another consortium within the Netherlands who also have 
evidence-based guidelines available for clinical practice.  Between the two consortiums, 
there are 78 evidence-based guidelines available to prescribing providers for guidance on 
various medications in clinical practice (Whirl-Carrillo et al., 2012).  
  The use of the PharmGKB website at Stanford houses the CPIC and DPWG 
clinical guidelines and continues to add to the science by conducting an analysis of 
applicable publications which may be utilized in clinical practice (PharmGKB, 2015).  
The availability of these resources has aided the acceptability and clinical use of 
pharmacogenetics.  For example, the Food and Drug Administration (FDA) has 
approximately 120 medications which have metabolic relationships to specific genetic 
pathways and are listed in patient medication pamphlets (FDA, 2014; Haga, Mills, & 
Bosworth, 2014).  Please refer to Appendix B for clinical guideline resources and 
education in pharmacogenetics.  
 Other contributions to the clinical use of pharmacogenetics include decreasing 
costs and increasing research interest and knowledge.  Costs for processing 
pharmacogenetic samples have decreased as technology has advanced, causing an 
increase in research interest and clinical practice (Wu & Fuhlbrigge, 2008).  These 
research interests have focused on specific allele groups and their effect on medications. 
Alleles are one of two forms of a gene that have occurred because of mutations, 
substitutions or deletions of nucleotides or proteins and result in different physical traits 
or phenotypes.  Having blue eyes or having a CYP 450 pathway with poor metabolic 
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enzyme activity, both represent phenotypes  (Zhou et al., 2009).  An allelic composition, 
as it relates to pharmacogenetics, establishes the enzymatic abilities within the liver.  
Most medications are metabolized, or activated through the CYP 450 enzymatic system, 
and this accounts for how approximately 75% of medications are either activated or 
cleared from the body.  The remaining 25% are metabolized through alternative body 
systems, e.g. kidney.  (Furge & Guengerich, 2006; Guengerich, 2008). 
  Overall, pharmacogenetic testing includes evaluation of the genes responsible for 
enzyme production throughout the CYP 450 liver metabolic pathways (Ingelman-
Sundberg, 2001, 2004; Ingelman-Sundberg & Rodriguez-Antona, 2005).  Each genetic 
result provides a picture of how well or how poorly the enzyme functions in an individual 
pathway to either activate the medication or degrade the medication for elimination.  
Depending on the combination of alleles in the genes inherited by the parents,  a person 
may have normal metabolism, otherwise described as extensive metabolism (EM), 
intermediate metabolism (IM), poor metabolism (PM), or ultra-rapid metabolism (UR) 
(Ingelman-Sundberg, 2001, 2004; Ingelman-Sundberg & Rodriguez-Antona, 2005).  
These results affect the ability of the liver to either convert a medication to its active form 
or break down the medication for excretion.  When the enzyme activity is increased, as in 
ultra-rapid metabolism (UR), the medication will be quickly metabolized and the patient 
may not see the benefit of the drug or will not have benefit of the drug’s positive effects 
for the length of normal time metabolizers (EM) do (Mrazek, 2010b).  
 A clinical example of pharmacogenetics in practice was the point of an FDA 
warning regarding children and the use of post-surgical codeine in children who are ultra-
rapid metabolizers at CYP 2D6 (Food and Drug Administration, 2013).  When children 
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who are ultra-rapid metabolizers at CYP 2D6  have normal doses of codeine, the 
increased enzymatic activity converts codeine to morphine very quickly, which in turn 
increases morphine blood levels causing respiratory decreases or arrest (Food and Drug 
Administration, 2013), Poor metabolizers, on the other hand, are unable to break down 
the medication to convert it to morphine and therefore, may not perceive the benefit of 
the medication, plus may exhibit increases in side effects  (Mrazek, 2010b; Mrazek et al., 
2014).   
Pharmacogenetics in Mental Health 
 The primary CYP enzyme pathways involved in antipsychotic medication 
metabolism in the liver include; CYP 1A2, CYP 2D6, CYP 3A4, and CYP 2C19.  Within 
each CYP pathway, variability of allelic composition exists.  An allelic variant is an 
alternate form of a gene; one allele is inherited from each parent.  These allelic variations 
influence the metabolism of a drug (Guengerich, 2008).  Additionally, transporter and 
receptor genes are important in psychotropic medication metabolism and transport and 
include; OPRM1, SLC6A4, HTR2A, and COMT.   
 Indiana University website, http://medicine.iupui.edu/clinpharm/ddis/main-table, 
lists medications according to their major pathway of excretion or activation.  
Medications are classified as substrates, inhibitors, and inducers.  A substrate is a 
medication that passes through a specified CYP pathway, and the enzymatic activity 
breaks down the medication.  An Inhibitor is a medication that blocks or inhibits the 
enzymatic activity from breaking down another medication that utilizes the same 
pathway.  An inducer is a medication that increases the activity of the enzyme causing an 
increased rate of breakdown of a medication (Flockhart, 2007).   
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 The pharmacists working on the study have developed a table of psychotropic 
medication utilized in this study and their associated CYP pathways (Appendix C).  
Medications can be substrates, inhibitors or inducers of a CYP pathway.  For example, a 
substrate is a medication that utilizes the pathway, an inhibitor blocks the pathway for 
other medications, and an inducer increases the enzymatic breakdown of the medication 
(Zhou et al., 2009).  A table related to medications for this study indicates psychotropic 
medications that will be utilized in this study and denotes the CYP pathway utilized along 
with if the medication is a substrate, inhibitor or inducer of a CYP pathway (Appendix 
C).  Magro, Moretti, and Leone (2012) described types of interactions such as Drug-Drug 
Interactions (DDI), Drug-Gene interactions (DGI) and Drug-Drug-Gene Interactions 
(DDGI).  Commonly, Drug-Drug interactions are to blame for adverse drug reactions in 
persons taking two or more medications (Magro et al., 2012).  A recent study by 
Verbeurgt, Mamiya, and Oesterheld (2014) noted that in addition to DDI  there are DGI, 
and DDGI that take place.  These interactions are much more frequent than most realized.  
DDI’s are caused when two drugs alter another drug’s effect on the body or interfere with 
metabolism, distribution or excretion of another drug.  DGI’s are an interaction between 
the drug and genetic makeup of the person, such as interference in the liver’s CYP 450 
enzymatic pathways (Verbeurgt et al., 2014).  DDGI’s occur when there are drug-drug 
interactions and drug-gene interactions affecting several CYP 450 pathways (Verbeurgt 
et al., 2014).  This study notes that DDI’s account for 66.1% of interactions, but that the 
remaining 33% were associated to DGI, and DDGI’s (Verbeurgt et al., 2014).  
Accounting for this information, it suggests that pharmacogenetic testing may increase a 
provider’s ability to prescribe a drug that will not cause adverse effects. 
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 The pharmacogenetic report will include the genetic results and medication 
changes recommended by a pharmacist team.  The provider and patient communication 
will include an acknowledgment by the patient that their medications are based on their 
genetic profile.  The reports will include suggestions individualize to the patient’s current 
medication list and genetic profile.  For example, if a patient has a resulting genetic panel 
that results in poor metabolism of the CYP 2D6 pathway and is taking fluvoxamine, 
which is metabolized primarily by this pathway, an alternate medication recommendation 
would be provided.  Additionally, the report will list medications that should be avoided 
with this patient. 
Gaps between genetics and behavioral outcomes 
 Very little research has focused on the influence of having genetic testing on 
patient behavior, specifically pharmacogenetic testing.  Haga and LaPointe (2013) have 
speculated that the act of pharmacogenetic testing will increase a patient’s medication 
adherence.  Additionally, Haga and LaPointe (2013) point out other positive impacts of 
pharmacogenetic testing such as less need for medication dosing adjustments, fewer 
changes in medications, fewer side effects, and the potential of less time to therapeutic 
outcomes.  These factors may contribute to medication adherence after pharmacogenetic 
testing.  However, there is only one identified publication that has addressed these two 
topics together using pharmacy refill data (Fagerness et al., 2014). 
 Three studies addressed medication adherence in patients who have had genetic 
testing, two studies evaluated risk genes and medication adherence, while one evaluated 
pharmacogenetic testing and insurance information on medication refill data (Charland et 
al., 2014; Fagerness et al., 2014; Grant et al., 2009).  Grant et al. (2009) conducted a 
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survey of participants in type 2 diabetes trials with and without a diabetes and reported 
that they would be more likely to have higher motivation to change their lifestyle if they 
had a ‘high risk’ gene for diabetes.  Additionally, participants reported that they would be 
‘much more motivated’ to be compliant with their medications if they had the high-risk 
gene (Grant et al., 2009).  Additionally, Charland et al. (2014) evaluated adherence to 
statin medications after risk testing of the KIF6 gene which shows an increased risk for 
congestive heart disease, finding that adherence increased with the knowledge of the 
result of this genetic testing.  The difference here is that the KIF6 gene is a risk gene and 
does not affect medication metabolism.  However, the finding implies that having the 
genetic result of increased risk, increases a person’s motivation to become more 
compliant.  One recent study evaluated retrospective health claims and concluded that 
those participants who had pharmacogenetic testing were more adherent to their 
medication as noted by medication refill data (Fagerness et al., 2014).     
 Medication adherence and patient activation have been noted to be low in patients 
with mental health disorders (Gunn et al., 2012; R. Sacks et al., 2014; Whooley et al., 
2008).  As defined by Hibbard (2008) activation refers to how engaged one is in 
managing his or her healthcare and can change over time.  It follows that if 
pharmacogenetics may improve a patient’s medication adherence, which is a component 
of patient activation, overall activation may also improve.  The amount of activation a 
patient may have in his or her healthcare is variable based on patient interest, skills, and 
the capacity to understand the diagnoses (Von Korff et al., 1997).  
 Patient activation improves not only medication adherence but also health 
outcomes.  When a patient is activated or engaged in their healthcare, increases in health-
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related behaviors are noticed including improved diet, exercise and obtaining 
preventative screening tests (Hibbard et al., 2004).  Four studies indicated that high 
patient activation measures correlate to better health outcomes in biometric indicators of 
health such as blood pressures, HgA1C levels, cholesterol levels, and body mass index  
(Hibbard & Greene, 2013; Rogvi et al., 2012; R. Sacks et al., 2014; Skolasky et al., 
2011).  To date, there are no published prospective studies identified which have studied 
patient response to pharmacogenetic testing as a relationship to medication adherence and 
patient activation. 
 This research study seeks to address the gaps in the literature found regarding 
patient activation, medication adherence and pharmacogenetic testing in a mental health 
and chronic illness patient population.  The purpose of the study is to compare the 
outcomes of patient activation and medication adherence before and after medication 
recommendations have been made utilizing pharmacogenetic testing information in a 
chronic illness and mental health population.  Research is needed to explore 
pharmacogenetics and potential behavioral changes.  No published studies were found by 
this author addressing pharmacogenetics and patient activation.  Additionally, only one 
published study was found by this author which examined medication adherence as the 
relationship of medication refill data to pharmacogenetics.  No published studies were 
identified by this author evaluating pharmacogenetics in patients with complex medical 
and medication backgrounds including mental health diagnoses and chronic illnesses.   
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Theoretical Framework  
 Davies et al. (2010) introduced a theoretical framework targeted to the practicing 
clinician.  It was developed by evaluating challenges that clinicians face when choosing 
antipsychotic medications.  The challenges are that a provider must be aware of and 
knowledgeable regarding pharmacology of drugs, molecular genetics of drug targets, and 
genetics of drug metabolism to prescribe medications according to genetics.  The 
conceptual framework emphasizes the patient outcomes related to medication adherence, 
side effects of medications and effectiveness of the medications (Davies et al., 2010).   
  Within this conceptual framework, medication monitoring, medication planning, 
molecular genetics of drug absorption and metabolism and patient outcomes are 
described.  These elements will be incorporated into Orem’s theory of self-care to 
provide the framework and the theoretical basis for the study.  This study will be 
addressing the molecular genetics of drug targets and metabolism as they relate to patient 
adherence, activation and thus patient outcomes.  
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Figure 1.  Conceptual framework incorporating pharmacologic findings and 
pharmacogenetic evidence about atypical antipsychotic medications (AADs) into 
advanced psychiatric nursing practice Davies, M. A., Conley, Y., & Puskar, K. (2010). 
Incorporating evidence from pharmacologic and pharmacogenetic studies of atypical 
antipsychotic drugs into advanced psychiatric nursing practice. Perspectives of 
Psychiatric Care, 46(2), p.99 
 
Nursing Perspective 
 Dorothea Orem’s Self-Care Deficit Theory (SCDT) theoretical emergence came 
from influences of philosophers such as Aristotle, Thomas Aquinas, Harre and Wallace 
and influenced the assumptions underlying her theory (Orem, 2006).  In Orem and Taylor 
(2011, p. 36)’s last reflections on her philosophic determinants, it was expressed that she 
followed a “moderate realism”, which was clarified as a practical scientific method, with 
applications of nursing science to practical reality.  In an effort to define nursing science, 
the grand theory of SCDT emerged (Orem & Taylor, 1986, 2011).   
  Three mid-range theories, which are interrelated, comprise the grand theory of 
SCDT.  These intertwined theories include concepts, assumptions about the theory, and 
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interrelationships between the theories.  The three theories are; the Theory of Self-Care, 
Theory of Self-Care Deficit, and the Theory of Nursing Systems (Parker & Smith, 2010).  
Figure 2 illustrates how the Theory of Self-Care is a subset of the Theory of Self-Care 
Deficit, which is a subset of the overarching  
Theory of Nursing System.  
 
Theory of Nursing System   
 
 Theory of Self-Care Deficit  
  
Theory of Self-Care  
 
  
           
   
Figure 2. Constituent theories, the self-care deficit theory of nursing. 
Orem, D. (1995). Nursing Concepts of Practice (5th Ed.) St. Louis: Mosby. (p.172) 
 
Theory of Self-Care 
 The ideas behind self-care began with the simple question, “Why do people need 
nursing?” (Renpenning & Taylor, 2003, p. 261 of 6936).  The term was coined in 1956 
when Orem was describing nursing in an Indiana State Health report (Orem, 1971; Orem, 
2006).  The theory of self-care has three central concepts which include; self-care, self-
care agency and self-care requisites, as depicted in Figure 3 below (Denyes et al., 2001; 
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Nursing Development Conference Group, 1979).  Renpenning and Taylor (2003, p. 3816 
of 6936)  wrote from “personal knowledge”, one of the emergent definitions of self-care 
as; 
“Self-care is conceptualized as the personal care that human beings require each 
day and that may be modified by health care, environmental conditions, effects of 
medical care and other factors.”  
Person(s) in Life Situations
Managing and Attending 
To Self
With Requirements to 
Regulate Functioning 
And Development
With Power to Engage
In Self-Care
Engaging in Action 
To Meet Regulatory 
Requirements
Self-Care
Requisites
Self-Care
Agency
Self-Care
 
Figure 3. Denyes, M., Orem, D., & Bekel, G. (2001). Self-care: A foundational science. 
Nursing Science Quarterly, 14(1), p.49. 
 
 Self-Care.  The concept of self-care identifies the “self” as both the entity 
performing the action or the “action agent” and the recipient of care.  Self-care is 
purposeful behavior, which contributes to the overall wellness of an individual.  The 
presuppositions of self-care are that it is a learned, voluntary behavior and responsibility 
or a right of the individual to maintain health and wellness (Denyes et al., 2001; Nursing 
Development Conference Group, 1979).   
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 The propositions include understanding self-care from three perspectives that 
contribute to overall self-care and include; (a) conditioning factors, (b) 
psychophysiological factors contributing to health and disease states, and (c) behavioral 
resources and demands (Denyes et al., 2001).  Conditioning factors include; having 
abilities related to understanding self, having a self-concept, understanding family and 
social positions, along with maturity levels.  Psycho physiological factors which 
contribute to health include self-care maintenance or the ability to maintain balance 
within the self, ability to perform tasks to maintain health, and ability to obtain or have 
knowledge of what needs to be completed to maintain health.  For example, anything that 
disrupts the balance may cause illness and affect one’s abilities of self-care.  Moreover, 
self-care behavioral resources that include one’s motivation, and use of resources 
(Nursing Development Conference Group, 1979).   
 Self-care requisites.  Self-care requisites are generalized actions required to 
maintain a purpose.  Additionally, within self-care, there are three main categories of 
self-care requisites including; universal, developmental and health-derived (Orem, 2001; 
Renpenning & Taylor, 2003).   
  Universal self-care requisites include commonalities to all humans at all ages, 
such as the need to sleep, eat, and exercise.  Nurses have the ability to identify a patient’s 
maturation process and adapt nursing interventions towards those developmental 
requisites.  Developmental health care requisites occur across the lifespan and are the 
changes one has as one ages including cognitive and affective changes.  Health-derived 
requisites are biologically based changes to structure and function of the body and 
represent a need for nursing care (Orem, 2001; Renpenning & Taylor, 2003; Taylor, 
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Renpenning, Geden, Neuman, & Hart, 2001).  Orem (2001) identified six types of health-
derived requisites including; the ability to seek and gain medical assistance, identifying 
changes in one’s health status, following through with prescribed treatments, awareness 
of and attendance to negative effects of treatment, adjusting self-image as health status 
changes, and living with health conditions as they arise (Orem, 2001). 
 Renpenning and Taylor (2003) published collections of Dorothea Orem’s 
unpublished writings notes which had been presented at meetings.  This collection also 
refers to “therapeutic self-care demand” as a requisite.  Orem defines this as  
“ care measures or self-care or dependent-care practices which result from 
investigation of questions about how self-care requisites can be met under 
prevailing conditions” (Renpenning & Taylor, 2003, p. 3930 of 6936).   
Therefore, when self-care demand is overwhelming to the person’s self-care capabilities, 
nursing assistance is needed (Orem, 2006).  
 Self-care agency.  Self-care agency is the power and ability to care for the self, 
and therefore nursing agency is the capability, knowledge and insight into the patients 
needs as self-care agents with deficits (Renpenning & Taylor, 2003).  Motivation and 
motives are the basis for self-care agency along with action.  Motivation, however, is a 
complex concept with two actionable concepts; (a) there must be a deliberate goal 
seeking action; (b) There must be a relationship between the motivation and deliberate 
action (Renpenning & Taylor, 2003).  In addition, there are six conditions that may 
promote self-care agency; (a) people must be knowledgeable to see what is good and bad 
in their pursuit of a goal; (b) people must have a reason that is personalized as desirable; 
(c) people need time to formulate and visualize a plan of action; (d) people should reflect 
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on their actions to determine suitability of the actions; (e) people should end their 
reflection time; (f) people must be responsible for their choice of action to attain the goal 
(Orem, 1987; Renpenning & Taylor, 2003).   
 Study framework.  Orem’s Theory of Self-care, patient activation, medication 
adherence and pharmacogenetic framework are used as the study’s complete framework 
to help describe the behavioral components of self-care after pharmacogenetic testing, 
and medication changes have been implemented.  This study will measure Patient 
activation (PAM-MH) and as evidence of the components of Self-Care, Self-Care 
Agency, and Self-Care Requisites.  For the pharmacogenetic testing framework for this 
study see Figure 4. 
 
Figure 4.  Patient activation as evidence of Self-Care. 
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Summary 
 This literature review and discussion of theoretical basis have identified the 
concepts that are significant to the design and implementation of this study.  The purpose 
of the study is to compare the outcome of patient activation before and after medication 
recommendations have been made utilizing pharmacogenetic testing information in a 
chronic illness and mental health population.   
 Studies have been conducted in patients with significant mental illness with 
regards to patient activation.  However, no studies identified by this author have 
addressed patient activation in patients who have had pharmacogenetic testing.  
Pharmacogenetics is gaining clinical acceptance as evidence for its applications within 
the mental health population grows.  No research exists related to behavioral outcomes of 
pharmacogenetic testing in this population.  Therefore, this study is designed to address 
the gaps in the literature as they relate to aspects of patient activation in patients with 
serious mental illness after pharmacogenetic testing and implementation.  This study will 
add to knowledge and understanding of behavioral aspects of pharmacogenetic testing 
and medication planning based on testing, patient activation and medication adherence.   
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CHAPTER 3 
DEPRESSION OUTCOMES IN CARE COORDINATION, PRIMARY CARE AND 
PSYCHIATRY PATIENTS AFTER PHARMACOGENETIC TESTING. 
Introduction to study changes 
  The study of patient activation in mental health patients after having 
pharmacogenetics care in a care coordination population was discontinued in January 
2016 due to an administration reason.  When the study concluded, there were 26 
participants with 100 required, and enrollment was progressing slowly.  This chapter 
discusses the combination of data from three studies.  The purpose of this dissertation 
study was to evaluate by provider types of care coordination, primary care and 
psychiatry, the change of depression severity (PHQ-9), depressive symptoms (QIDS-
SR16) and quality of life (SF-36) over time (T1-T3) in a population of patients diagnosed 
with MDD or DDNOS after having had pharmacogenetic testing.   
The data from the care coordination study was combined with data collected from 
two additional studies that evaluated pharmacogenetics testing in people diagnosed with 
depression.  All studies included a pharmacist guided medication recommendation for 
each participating patient, and these recommendations were given to providers in a report 
called the pharmacogenetics report (PGXr).  The term “pharmacogenetics care” will be 
used to represent the process of medication recommendation reporting based on genetics 
and genetic testing which occurred in all of these studies.  This process includes the fact 
that by entering the study and having genetic testing, study participants’ medications for 
depression were managed based on their genetics.  All studies were conducted with 
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patients who were diagnosed with new or current major depressive disorder (MDD) or 
depression disorder- not otherwise specified (DDNOS).  The similarities and differences 
of these studies will be explained. 
The main differences between the three studies was the type of provider managing 
the patient’s depression.  One study evaluated a population of patients who had 
specialists, psychiatrists, managing their depressive disorder.  This study will be referred 
to as ‘psychiatry’ throughout this document.  While the other two studies focused on 
patients, who were managed by primary care providers.  The care coordination study 
focused on patients with complex medical concerns under the management of a primary 
care provider and the patient was participating in care coordination.  The care 
coordination study utilized a nurse or social worker to help navigate through the health 
system and manage care.  The third study had depression management through primary 
care, and will be referred to as the ‘primary care’ study.  While patient activation was a 
component of the care coordination study, it was not included in the other two studies.  
Therefore, no patient activation data will be analyzed.   
All participants completed the same questionnaires including, a) an assessment of 
depression severity, Patient Health Questionnaire 9 (PHQ-9), b) an assessment of 
depression symptoms, The Quick Inventory for Depressive Symptoms- Self Report 
(QIDS-SR16) and c) an assessment of quality of life, The Short Form 36 (SF36).  
Additionally, questionnaire collection was completed on the same timeline and visit 
schedules in all three studies.  Completion of questionnaires occurred at baseline (T1), at 
the time the pharmacogenetics medication recommendations report (PGXr) was returned 
to their provider, (T2), and one month after medication changes were made (T3).  
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Demographic information such as age, marital status, insurance type, number of mental 
health diagnoses, and number of chronic health conditions were also collected.   
 These three depression studies were designed to evaluate the use and impact of a 
comprehensive pharmacogenetic report prepared by genetic pharmacists in the three 
settings.  All three groups received pharmacogenetic testing, and providers were given a 
pharmacists guided report with medication recommendations based on the patient’s  
genetics.  Patients acknowledged that they would have medications modified based on 
this genetics report during the consenting process, and subsequent provider discussions 
regarding the report.   
The genetic reports took into account each patient’s genetic variants as they relate 
to their enzyme activity of drug metabolism.  The reports also included information 
related to interactions between genes and other medications, such as, drug-drug, drug-
gene and drug-drug-gene interactions (Magro et al., 2012; Verbeurgt et al., 2014).  The 
testing focused on genetic pathways associated with antidepressant and antipsychotic 
medications, see appendix A.  This report included a list of medications classified into 
three categories, “use as recommended”, “use with caution”, or “not recommended”, for 
each patient’s medication list.  This report was given to the providers at four weeks  or at 
12 weeks in two of the studies.  The care coordination study patients had reports prepared 
for providers at four weeks without randomization.  
In summary, these three studies shared a similar population of patients all of 
which had a diagnosis of depression (MDD or DDNOS), data from the PHQ9, QIDS-SR, 
and the SF-36, which were completed at the same intervals, and all studies had 
pharmacogenetic testing with comprehensive pharmacogenetic care (PGXr).  These 
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likenesses allowed for data combination and analysis. The three studies are described in 
detail.  (Table 1) describing similarities and differences of the three studies.   
Table 1  
Comparison of three provider types 
 
Care Coordination study 
The initial dissertation study is referred to as the care coordination study and was 
evaluating mental health patients’ activation in a care coordination population after 
receiving pharmacogenetic care.  This study enrolled patients with MDD or DDNOS.  In 
addition to these depression diagnoses, these care coordination participants had 
significant chronic illnesses and other mental health diagnoses in addition to depression.   
Patients typically enter care coordination through recommendations made by their 
primary care providers having met the criteria for the program.  Care coordination 
Study  Primary Care 
Specialists Care 
(Psychiatry) 
Care Coordination 
Study 
population 
outpatient primary 
care 
outpatient 
psychiatric care 
outpatient primary 
care (care 
coordination 
participants) 
diagnoses 
depression (MDD 
or DDNOS) 
depression 
(MDD or 
DDNOS) 
*depression, bipolar, 
schizophrenia 
depression 
questionnaire 
PHQ9 PHQ9 PHQ9 
symptoms 
questionnaire 
QIDS-SR16 QIDS-SR16 QIDS-SR16 
Quality of life 
questionnaire 
SF-36 SF-36 SF-36 
Randomization 
PGXr received by 
provider at 4 weeks 
or 12 weeks 
PGXr received 
by provider at 4 
weeks or 12 
weeks 
No randomization 
occurred. 
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patients were accepted into the care coordination program based on the number of 
hospitalizations, number of medications and chronic diagnoses.  Tier selection based on 
hospitalizaitons and providers caring for the patient are presented (Table 2).  If a patient 
has more than two medications with a visit to the emergency department, and, at least, 
two providers, the patient could be admitted to the lowest level of care coordination.  The 
highest level of care coordination includes patients who were taking more than nine 
medications, has had two or more emergency room visits, two or more inpatient 
hospitalizations, and was seeing eight or more providers.  The care coordination patients 
had a nurse and a social worker assigned to them to help navigate the health care system. 
Table 2. 
Care Coordination Tiers    
Tier 1 Tier 2  Tier 3 Tier 4  
1 - 2 medications 3 – 4 medications 6- 8 medications 9 + medications 
1* ER visit 1 ER visit 2 ER visit 2+ *ER visits 
0 IP Admits 1 IP Admit 
2 IP Admits, 
including 1 
readmit 
2+ IP Admits 
including 2 
readmits 
1- 2 physicians 
providing services 
3- 4 physicians 
providing services 
5 –7 physicians 
providing 
services 
8+ physicians 
providing 
services 
*Hx: one diagnosis 
and/or complaint  
Hx:  2-3 diagnoses 
and/or complaints  
Hx: 4 – 5 
diagnoses and/or 
complaints 
Hx: 6 + 
diagnoses and/or 
complaints 
*Hx = History; ER = Emergency Room 
Primary Care study 
 Primary care providers who manage patients with depression were eligible to 
refer patients to this study.  All participants continued to work with their primary care 
providers for management of their depression.  Patients who qualified for this study must 
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have scored ten or greater on the Patient Health Questionnaire (PHQ-9) indicating current 
depressive symptoms and the need for treatment alteration or dose escalation.  A high 
score on the PHQ9, indicates more severe depression.  Participants had a baseline 
assessment of their depression severity (PHQ9), depressive symptoms (QIDS-SR16) and 
quality of life (SF-36).  This study was a six-month study, with blinded randomization.  
Patients were randomized to either having their provider receive their report at four 
weeks or 12 weeks, (Table 3).   
Psychiatry  
The Specialists study ‘psychiatry’ included the same population of patients.  
However, these patients were being provided care by psychiatry instead of primary care.  
All other assessments and randomizations were the same.  Data collection and timing 
were similar in all studies (Table 1) (Table 3).   
Randomization in two of the three studies 
 Participants in the primary care and psychiatry studies were randomized to 
receive the PGXr at four weeks or twelve weeks.  Participants who were randomized to 
the four-week arm of the study, were assessed by their first and third visits; baseline (T1), 
and one month after recommendations had been made (T3).  The participants who 
received randomization at 12 weeks were assessed at baseline (T1), at the time they 
received PGXr at 12 weeks (T2) and one month after receiving their reports (T3).  All 
patients completed the same assessments including the PHQ-9, QIDS-SR, and the SF36 
at each visit.  Evaluations and timelines are presented in (Table 1) and (Table 3) for the 
evaluations and timeline.  All three studies were approved by the health systems local 
Institutional Review Board.  See appendices D for the Institutional Review Board 
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approval, E for the Informed consent and supporting documents, F for the patient 
invitation letter, G for IRB approval Amendment 2. 
Table 3 
Data collection time-points 
ALL STUDIES COLLECTED 
  Baseline PGX results 
1 month after results 
returned 
Assessment T1 T2 T3 
PHQ-9 x x x 
QOL x x x 
QIDS-SR x x x 
T1 = Time 1, T2 = Time 2, T3 = Time 3 
 Problem statement 
Depression is a significant problem in the United States, and many who suffer 
from depression do not achieve remission of depressive symptoms and, or, develop side 
effects from medications (Ishak et al., 2013; World Health Organization, 2015).  In a 
literature search, there were three sentinel studies identified, indicating comparisons of 
primary care and psychiatry providers, but no studies were identified that evaluated 
depression outcomes of patients participating in care coordination with comparisons to 
primary care or psychiatry patients (Gaynes et al., 2005; Gaynes et al., 2007; Simon, Von 
Korff, Rutter, & Peterson, 2001).   
A study by Simon et al. (2001) concluded that both primary care and psychiatry 
patients had improvement in their depression and quality of life scores, and reported that 
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there were not any differences of depression severity between the two groups  (Simon et 
al., 2001).  Gaynes et al. (2007) findings supported that primary care and psychiatry 
providers have similar outcomes and have patients with similar depression severity.  On 
the other hand, conflicting information was found regarding suicidal ideation.  The study 
by Gaynes et al. (2005) indicated that those patients who were managed by psychiatrists 
had a higher incidence of suicidial ideation and past suicide attempts compared to 
primary care patients, but then found later that suicidal ideation was equal in both 
provider groups.  This study also reported that primary care patients were less likely to 
self-select as  having a depressed mood and had the inability to experience pleasure, i.e., 
anhedonia, indicating a potential to under report symptoms (Gaynes et al., 2005). 
The study by Simon et al. (2001) also found that there were deficiencies in both 
primary care and psychiatry providers, such as poor follow-up with patients after they 
leave the clinic.  The study also recommended adding more care management options to 
improve patient compliance and potentially outcomes (Simon et al., 2001).  In fact, a 
study completed earlier by the same group identified that when a patient has systematic 
follow-up from a care manager, depression did improve (Simon & Ludman, 2000).  
However, a comparison of care management such as care coordination to both primary 
care and psychiatry was not identified in a literature review.  The literature review did not 
reveal any commparisons of baseline differences in depression, or changes over time 
between a care coordination population compared to those patients who are managed by 
primary care or psychiatry. 
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Table 4 
Comparison of three studies 
*Care coordination allowed additional diagnoses as listed 
 Purpose of this study 
 The purpose of this study was to evaluate by provider types including care 
coordination, primary care and psychiatry, the change of depression severity (PHQ-9), 
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a 
population of patients diagnosed with MDD or DDNOS after having had 
pharmacogenetic testing.   
Research questions 
1.  Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in depression severity (PHQ9) over time (T1-T3) 
based on the type of provider?  
Study  Primary Care 
Specialists Care 
(Psychiatry) 
Care Coordination 
Study 
population 
outpatient primary 
care 
outpatient 
psychiatric care 
outpatient primary 
care (care 
coordination 
participants) 
diagnoses 
depression (MDD 
or DDNOS) 
depression 
(MDD or 
DDNOS) 
*depression, bipolar, 
schizophrenia 
depression 
questionnaire 
PHQ9 PHQ9 PHQ9 
symptoms 
questionnaire 
QIDS-SR16 QIDS-SR16 QIDS-SR16 
Quality of life 
questionnaire 
SF-36 SF-36 SF-36 
Randomization 
PGXr received by 
provider at 4 weeks 
or 12 weeks 
PGXr received 
by provider at 4 
weeks or 12 
weeks 
No randomization 
occurred. 
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a. Hypothesis 1: Depression severity scores (PHQ9) among patients who 
receive care coordination will decrease over time. 
b. Hypothesis 2: Depression severity scores (PHQ9) among patients who 
receive care by a Primary care provider will decrease over time. 
c. Hypothesis 3: Depression severity scores (PHQ9) among patients who 
receive care by a Psychiatrist will decrease over time.   
2. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in depression symptoms (QIDS-SR16) over time 
(T1-T3) based on provider type? 
a. Hypothesis 1: Depression symptom scores (QIDS-SR16) will decrease 
over time (T1-3) among patients who receive care coordination. 
b. Hypothesis 2: Depression symptoms scores (QIDS-SR16) will decrease 
over time (T1-T3) among patients who receive Primary care services. 
c. Hypothesis 3: Depression symptoms scores (QIDS-SR16) will decrease 
over time (T1-T3) among patients who receive care through psychiatry. 
3. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in the physical components (physical functioning, 
role physical, bodily pain, general health) of the SF-36 scale by provider type? 
a. Hypothesis 1: Overall physical component scores (PCS) of the SF-36 scale 
will be highest in psychiatry and primary care, and lowest in care 
coordination.   
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b. Hypothesis 2: When comparing by provider types, physical functioning 
scores in the SF-36 scale will be the highest in psychiatry and primary 
care and the lowest in care coordination. 
c. Hypothesis 3: When comparing by provider types Role Physical scores in 
the SF-36 scale will be highest in psychiatry, and primary care and lowest 
in care coordination. 
d. Hypothesis 4: When comparing by provider types, Bodily Pain scores in 
the SF-36 scale will be highest in psychiatry and Primary care and lowest 
in care coordination. 
e. Hypothesis 5: When comparing by provider types, General Health scores 
in the SF-36 scale will be highest in psychiatry and Primary care and 
lowest in care coordination. 
4. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in the mental components (vitality, social function, 
role emotion, and mental health) of the SF-36 scale by provider type? 
a. Hypothesis 1: When comparing by provider types, mental composite 
scores of the SF-36 scale will be highest in primary care and care 
coordination and lowest in psychiatry.  Hypothesis 2: When comparing by 
provider types, Vitality scores in the SF-36 scale will be the highest in 
primary care and care coordination and lowest in psychiatry. 
b. Hypothesis 3: When comparing by provider types, Social function scores 
in the SF-36 scale will be the highest in primary care and psychiatry and 
lowest in care coordination. 
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c. Hypothesis 4: When comparing by provider types, Role Emotional scores 
in the SF-36 will be the highest in primary care and care coordination and 
lowest in psychiatry. 
d. Hypothesis 5: When comparing by provider types, Mental Health scores 
will be the highest in primary care and care coordination and lowest in 
psychiatry. 
5. How does the study population’s genetic phenotype (poor metabolizer, 
intermediate metabolizers, ultra-rapid metabolizer) in all provider types compare 
to the general population genetic phenotypical frequency rates?  
Summary of study changes 
 This study evaluated the provider types of care coordination, primary care and 
psychiatry providers, changes in depression severity (PHQ9), depression symptoms 
(QIDS-SR16) and quality of life (SF-36) over time after having pharmacogenetics 
testing.  Data from three studies were combined in a population of patients newly or 
currently treated for MDD or DDNOS.  All participants had a personalized pharmacist’s 
guided report based on their current medications and genetic testing.  The similarities of 
the three studies in patient population, questionnaire completion and timing of visits were 
similar to allow comparisons between patients managed by each of the three provider 
types. 
Literature Review 
This review will provide a brief summary of the literature found to support the 
need for this study.  The purpose of this study was to evaluate by provider types of care 
coordination, primary care and psychiatrists, the change of depression (PHQ-9), 
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depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time in a population 
of patients diagnosed with MDD or DDNOS not in remission after having had 
pharmacogenetic testing.  The following topics were explored in this literature review 
including depression as was related to the following areas; the prevalence, characteristics 
in primary care and psychiatry practices, and care coordination and quality of life.   
Depression 
Worldwide 350 million people suffer from depression, and in the United States, 
the number suffering from depression is approximately 40 million (World Health 
Organization, 2015).  This number represents primarily women and is the cause of 
approximately 800,000 suicides every year (World Health Organization, 2015).  Pratt and 
Brody (2008) note that depression varies by socioeconomic status, age, sex and race.  
Regarding socioeconomic status, those who fell below the federal poverty level and were 
women age 40-59 had the highest incidences of depressive episodes (Pratt & Brody, 
2008).  Depression causes functional changes in one’s ability to perform daily activities, 
get along with others and work (Pratt & Brody, 2008).  The Diagnostic and Statistical 
Manual of Mental Disorders-Revised 5th edition criteria includes the notation of positive 
indicators of five out of nine  symptoms such as depressed mood, decreased interest or 
pleasure, changes in weight, changes in sleep, changes in activity, increased fatigue, 
increased guilt, changes in concentration and suicidality (American Psychiatric 
Association, 2013).  Additionally, poor quality of life has been shown to be associated 
with depression and reported to be an important factor related to understanding 
depression (Bonicatto, Dew, Zaratiegui, Lorenzo, & Pecina, 2001; Doraiswamy, Khan, 
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Donahue, & Richard, 2002; Papakostas et al., 2004; Saarijarvi, Salminen, Toikka, & 
Raitasalo, 2002; Trivedi et al., 2006) 
10 
A literature review was conducted using the terms ‘depression’ and ‘psychiatry or 
psychiatric or mental health’ and ‘primary care’, through EBSCOhost with all databases 
chosen, which yielded 2,668 articles.  Limiting the search to full-text, and between the 
dates of 2010-2016, the number of articles resulted in 732.  Topics of maternal mental 
health, perinatal mental health, child *.*, and veterans were excluded, 552 articles were 
returned.  From these articles three sentinal articles were identified which totaled 13 
articles reviewed. 
Many studies identify a need to meet evidence-based standards in  primary care 
and a need to improve training in primary care (Mechanic, 2014).  The literature search 
was rich with articles regarding primary care and its ability to identify patients (Lemelin, 
Hotz, Swensen, & Elmslie, 1994), screen (Tiemens, VonKorff, & Lin, 1999), treat and 
refer to psychiatry (Ferguson, 2000).  Indirect comparisons of provider types have 
reported that specialty care was more expensive but most effective in treating depression 
(Sturm & Wells, 1995).  One study, which lacked sample size, showed significance 
toward the superiority of primary care to specialty care for treatment of depression (Scott 
& Freeman, 1992).  Direct comparisons of primary care and psychiatry have been 
conducted in regard to depression severity and outcomes (Gaynes et al., 2005; Gaynes et 
al., 2007; Howland, 2008; Rush, 1993; Simon et al., 2001), and medication prescribing 
(Mayor, 2015). 
57 
  
The earliest comparisons of primary care and psychiatry patients indicate that 
initial depression severity and number of medical diagnoses were similar in both provider 
types (Simon et al., 2001).  This study also concluded that over time both primary care 
and psychiatry patients had improvement in their depression and quality of life scores, 
but there were not any differences between them (Simon et al., 2001).  Also, it was 
observed that there were deficiencies in patient care by both groups, as exampled by poor 
follow-up with providers.  Furthermore,  this study added that more care management 
options would improve patient compliance (Simon et al., 2001).  In fact, a study 
completed earlier identified that when a patient has systematic follow-up from a care 
manager, depression did improve (Simon & Ludman, 2000).  However, a comparison of 
care management such as care coordination to both primary care and psychiatry has not 
been reported.  
Two recent studies published by Gaynes et al. (2005); Gaynes et al. (2007) 
assessed the differences in those patients who sought treatment management by a primary 
care provider or by a psychiatrist.  These studies had similar results to Simon et al. 
(2001), reporting that the depression severity between the two groups was similar. 
However, the study by Gaynes et al. (2005) indicated that those patients who were 
managed by psychiatrists had a higher incidence of suicidal ideation and past suicide 
attempts compared to primary care.  In the 2005 study by Gaynes et. al, primary care 
patients were also less likely to self-select having a depressed mood and anhedonia.  The 
next study Gaynes et al., (2007) conducted included 1,000 more participants and asked 
similar questions.  This subsequent study confirmed findings of equal depression 
severity, and depression symptom distribution in both primary care and psychiatry groups 
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(Gaynes et al., 2007). However, when suicide was assessed, it was also found to be equal 
in both groups for suicide attempts and suicidal ideation, which contradicts the previous 
report that psychiatry had higher suicide rates (Gaynes et al., 2007) 
Care coordination and depression 
Literature reviews of EBSCOhost with all databases chosen for the words ‘care 
coordination’, and ‘depression’ returned 377 articles.  When children and veterans were 
excluded 199 articles were returned and ‘health to home’ was added a return of 7 articles 
which were unrelated to the dissertation topic were returned.  Limiting to full-text 
available and peer review, decreased the 199 articles to 100.  No studies were identified 
specifically indicating depression care in care coordination.  Some topics revealed ‘case-
management’, ‘stepped-care’, ‘collaborative models’.  Searches of these and article 
bibliographies such as from the American Nurses Association and the Institute of 
Medicine discussions regarding care coordination, 17 articles for this review were 
identified.  Because few results returned articles specific to care coordination, case-
management or care management will also be discussed.  
While case-management is slightly different than care coordination, case-
management provides information regarding improving outcomes for patients associated 
with guidance within the health care system (Gensichen et al., 2013).  Collaborative Care 
is another model using professional collaboration, evidence-based protocols and has a 
focus on long-term outcomes of patients with chronic conditions (Gunn et al., 2012).  
Case-managers can be master’s prepared nurses, who orgainize and coordinate care 
services to maintain continuity of care and minimize costs .  Care coordination has many 
more definitions identified and encompases more scope than case-management 
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(McDonald et al., 2014; McDonald et al., 2007; Schultz, Pineda, Lonhart, Davies, & 
McDonald, 2013).  Because of the large overlap of practice and extreme similarities 
between case-management and care coordination, case-management was included in the 
literature review.  
Ekers et al. (2013) conducted a meta-analysis of published studies which used 
collaborative care model to evaluate its effectiveness in  managing patients with 
depression.  This meta-analysis evaluated the results of 14 randomized studies and 
reported that patients who are managed by nurses and have long-term chronic illnesses 
have better outcomes than without nurse management (Ekers et al., 2013).  Another study 
showed improvements in depression-free-days when case-management for depression 
was used in small practice settings (Gensichen et al., 2013).  A more recent study of care 
management for depression, found that patients involved in collaborative depression care  
had decreases in depression, were compliant with visits, medication, and follow-up with 
providers better than those who were not followed by care management (Palmer, 
Vorderstrasse, Weil, Colford, & Dolan-Soto, 2015).   
Care coordination was established in the 1990’s as a model used in several 
settings, such as health maintenance organizations (HMO’s), and the Centers for 
Medicare & Medicaid (Craig, Eby, & Whittington, 2011).  Care coordination is essential 
to providing quality care for individuals with complex medication regimens, medical 
histories, and chronic disease.  Plus it is effective for medical  and cost outcomes 
(American Nurses Association, 2012).  Nursing has been integral in providing evidence 
of the effectiveness of care coordination programs, such as care transitions to reduce 
rehospitalization , and effective coping to manage social issues of homelessness or food 
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insecurities (Coleman, Parry, Chalmers, & Min, 2006; Craig et al., 2011). Regarding 
mental health care coordination, studies have shown that telephone contacts  to follow up 
with patients, increase adherence to medication and follow-up appointments (Dietrich et 
al., 2004; Oxman, Dietrich, Williams, & Kroenke, 2002). 
Currently, the Centers for Medicare & Medicaid have a funded project to 
implement care coordination in care transitions of behavioral health to evaluate 
rehospitalization because of depression (Gold & Becker, 2015).  A report published since 
this announcement, documents that those patients hospitalized for serious mental illness 
who participated in the care transitions program, had better follow through rates with 
their primary care providers than their mental health providers after hospitalization 
(Domino et al., 2016).  This Domino et al. (2016) report indicates a close tie to primary 
care, and deficiencies in communication with specialty providers.  
A comparison of care providers may be helpful to identifing  interventions to care 
for patients with depression.  Care coordination programs have been supported by the 
American Nurses Association and a white paper describes the pivotal, and important role 
that nursing makes in this program (American Nurses Association, 2012).  Care 
coordination has shown improvements for patient’s quality of care, ability to decrease 
costs, and improve survival rates.  Yet, in a literature search, no studies were identified 
that compared care coordination with primary care or psychiatry providers. 
Depression and quality of life 
 A search for the term “depression” and “quality of life” on EBSCOhost with all 
databases chosen, yielded 54,405 articles.  Limiting it to peer-reviewed scholarly articles, 
full articles available and reducing the years from unlimited to the last three years, the 
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result were 15, 754.  When the terms “pharmacogenetics” was added, two articles were 
returned which were not supportive to this dissertation.  When the same search of the 
three terms was conducted in PubMed, 13 articles were returned, three were disregarded 
because they were duplicates.  From these articles bibliographies, and bibliographies of 
other identified articles, the following review included 10 articles. 
Quality of life includes three main components, physical functioning, social 
functioning, and emotional functioning (Ware, Kosinski, & Keller, 1996; Ware & 
Sherbourne, 1992a).  It is well established that a poor depressive prognosis is associated 
with poor quality of life (Bonicatto et al., 2001).  In a study of depressed persons, it was 
reported that those who were depressed reported a forty percent impairment in quality of 
life when compared to those who are not depressed (Ishak et al., 2013).  Factors 
significantly contributing to decreases in quality of life in the depressed population may 
be associated to depressive symptomology, disability, and age (Ishak et al., 2013).  
Depression has an impact on not only mental quality of life but physical 
functioning, perceived bodily pain and a person’s feelings of general wellness (Saarijarvi 
et al., 2002).  The SF-36 evaluates eight domains that make up overall quality of life. 
These include; physical functioning  (PF), physical limitations because of health 
problems (RP), physical, body pain (BP), general perceptions regarding health (GH), 
vitality (VT), social functioning (SF), limitations due to social or emotional problems 
(SE), and mental health (MH) (McHorney, Ware, & Raczek, 1993). 
  Bonicatto et al. (2001) reported poorer quality of life in persons with depression 
than those with or without chronic conditions, which indicates the extent of the impact 
depression may have on health outcomes.  Similar results were found in an elderly 
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population noting that quality of life in depressed persons was at least as debilitating as a 
chronic physical condition (Doraiswamy et al., 2002).  Additionally, as age increases, 
physical quality of life decreased.  Interestingly, the elderly tended to have higher scores 
overall on the quality of life measure indicating that with age people are more content 
overall (Doraiswamy et al., 2002).  Understanding the impact of physical health to mental 
health can give a more impactful view of depression and its treatments (Ishak et al., 
2013).  Not all studies report positive outcomes for those with improvement in 
depression.  One study reported that only fifty percent of patients who were in remission 
for depression, improved quality of life scores  (IsHak et al., 2015). 
Physical quality of life has been recently evaluated in bipolar participants of the 
Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD) study to 
examine the relationship of physical quality of life and bipolar symptoms.  The analysis 
revealed that Role physical and General Health scores within the Short Form 36 survey 
were related to and predicted worsening depression.  Also, those who reported fewer 
depressive symptoms had fewer physical limitations (Bernstein et al., 2016).  The 
impairment in quality of life for persons with depression and the additional impact on 
physical health indicates a need to understand physical symptoms associated with 
depression in addition to quality of life (Ishak et al., 2013).  Having chronic conditions 
could explain why those with remission of depression continue to have decreased quality 
of life scores (Alonso et al., 2004).   
 The literature review reveals that more research is needed in the use and 
effectiveness of a locally developed multi-gene assessment to guide provider 
pharmacotherapy prescribing.  Also, when considering other published studies that 
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include a comprehensive pharmacogenetic report related to psychotropic medications, it 
is interesting to note that quality of life has not been addressed (Altar et al., 2015{Hall-
Flavin, 2013 #242).  The STAR*D literature indicates the need for quality of life 
assessment to more fully understand patients and their depression symptoms (Trivedi et 
al., 2006).   
Theoretical Framework  
 The theoretical framework for this new study had no changes from the previous 
study and is as described in chapter one and two.   
Nursing theory  
The nursing theory used was Orem’s Theory of Self-care.  This is unchanged 
from Chapter one and two.  The new model appears below in Figure 5.  This illustrates 
changes in depression severity, depression symptoms and quality of life without regard 
for provider type.  However, the awareness of having pharmacogenetic care, may impact 
a patient outcome positively.  Some authors have indicated that this is a placebo effect 
(Haga, Warner, & O'Daniel, 2009) 
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Patient after Start of 
Pharmacogenetic care
(T1 to T2)  and 
Pharmacogenetic Care 
(T2 to T3)
SELF-
CARE
SELF-CARE 
AGENCY
SELF-CARE 
REQUISITES
Person(s) in Life Situations Managing 
and Attending  to Self
Quality of Life (SF-36)
Depression (PHQ-9)
Depression Symptoms 
(QIDS-SR16)
Patients before
Pharmacogenetic Care: 
Time 1 
SELF-
CARE
SELF-CARE 
AGENCY
SELF-CARE 
REQUISITES
Quality of Life (SF-36)
Depression (PHQ-9) 
Depression symptoms 
(QIDS-SR16)
Person (s) in self-care deficit
Awareness of current medication  regime Awareness of medications based on genetics
 
Figure 5. Depression severity (PHQ9), depression symptoms (QIDS-SR16), and quality of 
life (SF-36), as they are associated to Self-care deficit.  
 
Study significance  
In consideration of providers, nurse prescribers, and other professions working 
with patients, opening communication between the provider and patient because of 
pharmacogenetic testing may increase patient’s quality of life, and decrease depression 
severity and symptoms.  Furthermore, increases in quality of life may promote patient’s 
active participation in self-care behaviors, decrease missed clinic visits and promote the 
intentional and appropriate use of resources.  Few differences have been identified 
between primary care and psychiatry in studies to date.  However, indications that 
managed care may be beneficial to depression outcomes can be evaluated through a 
comparison of care coordination to primary care and psychiatry.  Current literature was 
not identified that show evidence of what differences might be found between these 
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populations.  The American Nurses Association (2012) provides primary evidence to the 
impact that nursing can make on the outcomes of patients who are participating in care 
coordination.  Nursing is poised for providing interventions which may be helpful to care 
coordination participants with depression.  
Methods 
The purpose of this dissertation study was to evaluate by provider types of care 
coordination, primary care and psychiatry, the change of depression severity (PHQ-9), 
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a 
population of patients diagnosed with MDD or DDNOS after having had 
pharmacogenetic testing.  The methods section will discuss study design, population, 
study data collection, instruments used, and statistical analysis. 
Study Design 
This study was an analysis of data from three similar studies evaluating MDD and 
DD-NOS.  The data from these three studies were combined.  All of the studies utilized a 
prospective, repeated-measures design and two of the studies were randomized 
prospective repeated-measure designs.  
Sample and Setting 
This study was conducted in collaboration with a large health care system, clinics, 
and hospitals in the upper Midwestern United States.  The health system covers over 
70,000 members in three states, and there are over 300 facilities within the health system.  
This study focused on participants in three studies of pharmacogenetics in patients who 
had a diagnosis of depression and who had completed three visits.  The three key visits 
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analyzed included a baseline visit (T1), a visit at pharmacogenetics reporting (T2), and a 
visit after pharmacogenetic report (PGXr) has been given to providers (T3).  If the 
subject were in a study that had randomized pharmacogenetics results given to the 
provider at 12 weeks, the same data collection points would be utilized.  However, there 
would be different time intervals between data collection points.  For example, a patient 
who is randomized to “twelve-week reporting”, will receive a pharmacogenetics report 
eight weeks after the patient who is randomized to “four-week reporting” (Table 4) 
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Table 5 
Three study randomizations  
Primary care and Specialists care: RANDOMIZED TO 4 WEEKS 
weeks 0 4 8 12 16 18 
Time point evaluated *T1 *T2 *T3       
Visit Number  V1 V2 V3 V4 V5 V6 
PHQ9 x x x x x x 
QIDS-SR16 x x x x x x 
SF-36 x x x x x x 
PGXr (randomized to 4 or 12 weeks)   x  x     
    
**data not utilized 
for this analysis 
Primary care and Specialists care: RANDOMIZED TO 12 WEEKS 
weeks 0 4 8 12 16 18 
Time point evaluated *T1     *T2 *T3   
Visit Number  V1 V2 V3 V4 V5 V6 
PHQ9 x x x x x x 
QIDS-SR16 x x x x x x 
SF-36 x x x x x x 
PGXr (randomized to 4 or 12 weeks)   x   x    
Care Coordination study: had no randomization 
weeks 0 4 8 12 16 18 
Time point evaluated *T1 *T2 *T3       
Visit Number  V1 V2 V3 V4 V5 V6 
PHQ9 x x x x x x 
QIDS-SR16 x x x x x x 
SF-36 x x x x x x 
PGXr   x         
*Time points evaluated for this study. 
Population 
The sample population included participants in three studies of depression and the 
criteria for this analysis included the following: 
Inclusion criteria 
1. The participant had a diagnosis of MDD or DDNOS. 
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2. The participant had completed informed consent for the study in which they 
were enrolled. 
3. All participants in the study were evaluated regardless of how many visits 
they had completed. 
4. The provider managing the patient’s depression (primary care or specialist) 
consented to the patient’s participation in the study. 
5. Participants were 18 years old or older, males or females. 
6. Participants were taking, or the provider planned on starting, an antidepressant 
medication to be included in the study. 
7. Participants who had a history of substance abuse, other than nicotine, had to 
be stable in the opinion of the principal investigator and provider.  
8. Participants had a life span expectancy of a year or longer.  
9. Subjects must have been able to read and write in English. 
Exclusion criteria. All patients met the exclusion criteria to participate in the dissertation 
research.  
1. Participants were not pregnant or breastfeeding mothers. 
2. Participants were not younger than 18 years old. 
3. Participants did not have a primary diagnosis of Dementia, bulimia, or anorexia 
nervosa disorder diagnosis. 
4. Participants who had a previous pharmacogenetic evaluation were excluded. 
5. Participants who had disorders affecting drug absorption (i.e., Crohn’s Disease 
or Colitis, significant surgical procedures affecting medication or food 
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absorption, or conditions as identified by the principal investigator to interfere 
with medication absorption). 
Recruitment.  Recruitment was described in the “care coordination” dissertation 
chapters’ methods section.  Recruitment for those in the ‘primary care provider’ or the 
‘specialists (psychiatry) studies occurred through provider referral to the study staff of 
those studies.  Primary care participants were recruited from various clinics and hospitals 
throughout the health system, and all study visits were completed over the phone.  
Questionnaires were mailed to participants and follow-up phone calls made as needed.  
The specialists (psychiatry) study participants were referred by their psychiatrist and 
were seen in the psychiatrist’s office.  All questionnaires for these patients were 
completed in person at the psychiatry office.   
Study Schedule.  For this study regardless of randomization, the study visits 
assessments included the baseline, the visit at which the PGXr was given to the provider, 
and one month after the pharmacogenetics report was received (Table 3 and 4) 
Data Collection 
Instruments 
Patient Health Questionnaire-9 (PHQ9).  The PHQ9 is a 9-item, self-report 
measure of depression severity, scored from zero to 27.  Each of the nine questions have 
four answer options (0-3) defining the severity and, or frequency of symptoms over the 
past two weeks; zero denotes ‘no symptoms at all’.  A score of 1 represents symptoms are 
experienced ‘several days’, and a 2 indicates that symptoms are experienced ‘more than 
half the days’.  The highest score, 3, signifies ‘nearly every day’ symptoms are 
experienced.  The instrument evaluates the previous two weeks.  PHQ9 scores ranging 
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from 0-4, were minimal depression, 5-9 indicate mild depression, 10-14 represent 
moderate depression, 15-19 designate moderately severe depression and more than 20 
designates severe depression (Kroenke, Spitzer, & Williams, 2001; Manea, Gilbody, & 
McMillan, 2011). 
When the PHQ9 was evaluated and compared to independent physician diagnosis, 
it was found to be accurate at 85%, have 90% specificity, with a sensitivity of 90% 
(Spitzer, Kroenke, & Williams, 1999). The PHQ9 has a reported Cronbach’s alpha of 
0.85 indicating good internal reliability, and Spitzer et al. (1999) reported criterion 
validity based on the concurrence of diagnoses indicated by individual providers 
compared to the PHQ9.  Construct validity was strong when SF-20 was compared to 
PHQ9 measurement indicated that as PHQ9 scores rise, patient’s functional status 
decreases on the SF-20. 
Quick Inventory of Depressive Symptomology-Self Report 16 (QIDS-SR16).  
The QIDS-SR 16 was developed from a 30 Item Inventory of Depressive Symptomology 
(IDS30) to decrease the length and develop a self-report scale and clinician’s rating scale 
(Rush, Gullion, Basco, Jarrett, & Trivedi, 1996; Rush et al., 2003).  This scale was 
evaluated against the Hamilton Depression Scale (HAMD24) which has (Cronbach’s 
alpha = 0.88) high internal consistency (Rush et al., 2003).  The internal consistency of 
the QIDS-SR16 was also found to be high (Cronbach’s alpha = 0.92), and total scores are 
predictive of HAMD17 scores by multiplying 1.3 times the total QIDS-SR16.  
Additionally, high relative validity has been established with other instruments including 
the HAMd24, HAMD17, QIDS30, and MADRS (Carmody et al., 2006).  A comparative 
table is available for HAMD24, HAMD17, and QIDS30 (Rush et al., 2003). 
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 The QIDS-SR16 is a self-report tool which evaluates nine domains including a) 
sad mood; b) concentration; c) self-criticism; d) suicidal ideation; e) interest; f) 
energy/fatigue g) sleep changes including initiation of sleep, middle and late insomnia or 
hypersomnia; h) increased or decreased appetite/weight; i) psychomotor 
agitation/retardation.  Each domain has two to three questions associated with it for a 
total of sixteen questions.  Each of the nine items is scored with a value given from 0-3 
for each answer.  The highest item score within a domain is chosen as the final score for 
that domain.  The total scores for the nine domains may range from zero to twenty-seven.  
Twenty-seven reflects the most severe symptoms related to depression.  Mild depression 
is scores of six to ten, 11-15 is moderate, 16-20 is severe and more than 21 is very severe 
depression (Rush et al., 1996; Rush et al., 2003; Trivedi et al., 2004).  
Short Form 36 (SF-36) Health Survey.  The Short Form-36 (SF-36) Health 
Survey for measuring quality of life, was developed to understand health outcomes in 
population health, clinical health initiatives, and research in many different disease states 
that include pain, cardiovascular disease, cancer and psychiatric diagnoses as some of the 
most prolific uses.  It has been widely published with over 4,000 publications using this 
instrument to measure health outcomes (Turner-Bowker, Bartley, & Ware, 2002). 
 The quality of life measure, the SF-36  is a 36 item self-report instrument, using 
both five-point and 3 point Likert scales.  The five-point scale goes from a score of zero 
to five, zero being severe symptoms and five being no symptoms.  The three-point scale 
is used, for example, when asked about physical limitations and zero indicates ‘yes, 
limited a lot’ while three indicates, ‘not limited.'  All subscales are scored from zero, 
which is severe symptoms to 100 which is no symptoms.  The subscales are combined 
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and averaged to create a ‘physical composite score’ and a ‘mental composite score’.  A 
zero represents poor quality of life, to 100 which is high quality of life.  The higher the 
score, the better quality of life is observed by participants.  McHorney et al. (1993); Ware 
et al. (1996); Ware and Sherbourne (1992a) explain the  eight domains of health 
including; ‘physical functioning’  (PF), physical limitations because of health problems-
‘role physical’ (RP), physical, ‘body pain’ (BP), general perceptions regarding health-
‘general health’ (GH), ‘vitality’ (VT), ‘social functioning’ (SF), limitations due to social 
or emotional problems ‘role emotional’ (RE), and ‘mental health’(MH).  The ‘mental 
composite score’ (MCS) and the ‘physical composite score’ (PCS) are averages of four 
related subscales.  The MCS includes PF, RP, BP, and GH.  The PCS includes VT, SF, 
RE, and MH.  The two scores which are commonly used are the PCS and MCS (Ware & 
Sherbourne, 1992b).  Each domain and meanings of each domain and what they represent 
are presented (Table 6).  Frendl and Ware (2014) evaluated pharmaceutical clinical 
studies that utilized the SF-36 and noted that there were significant changes in scores in 
several disease states, the top being rheumatoid arthritis, and psoriasis.  Depression was 
also noted to have good responses for changes in the SF-36 after beginning medication, 
which confirms the usefulness of the SF-36 in clinical trials utilizing drug therapy (Frendl 
& Ware, 2014).  
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Table 6 
SF36 subscales Low Scores (0 - 50) High Scores (> 50) 
Physical Composite 
Score     
physical functioning 
Unable to complete 
activities of daily 
living 
Completes activities 
of daily living 
without limitations 
role-physical 
Physical health 
interferes with work 
or job activities 
Physical health does 
not interfere with 
work activities 
Bodily pain Severe pain mild to no pain 
General Health 
Has the belief that 
health will become 
worse 
Has the belief that 
health will improve 
Mental Composite 
Score   
Vitality Low energy levels Has energy and pep 
Social Function 
physical or emotional 
problems interfere 
with social life 
There are no social 
life limitations 
because of either 
emotional or physical 
problems 
Role-emotional 
Emotional problems 
interfere with work or 
job activities 
No work or job 
interferences because 
of emotional 
problems.  
Mental Health 
Anxiety or sadness 
most of the time 
Feels happy and 
relaxed most of the 
time.  
 Ware and Sherbourne (1992a, p. 475) 
 Number of chronic conditions and mental health conditions.  The number of 
chronic conditions and mental health conditions was a tally of diagnoses, one number for 
a chronic condition and one number for mental health conditions as listed in the patient’s 
medical record and associated with an ICD-9 or ICD-10 code.   
Demographic Information.  Age, gender, type of medical insurance, marital status, and 
employment status were collected.   
Statistical Analysis 
74 
  
Sample size estimate.  Sample size was based on recruited patients up until 
January 2016 when the study was stopped.  Original sample size estimates were 100 per 
study based on the G*POWER sample size calculator.  The statistical plan is represented 
below (Table 7). 
Table 7 
Statistical plan 
Hypothesi
s 
Variable 
Type of 
Variable 
Comparison Statistical Test 
1 
PHQ9 -
Dependent 
discrete variable 
(nominal) 
PHQ9 at T1, T2, 
T3 
mixed linear 
models 
2 
QIDS-SR 
Dependent 
continuous/inter
val/ratio 
QIDS-SR at T1-3 
mixed linear 
models 
3 
QOL-Mental 
Health 
dependent 
continuous/inter
val/ratio 
QOL-MH at T1, 
T2, T3 
mixed linear 
models/ 
Jonckheere-
Terpstra 
4 
QOL physical 
health 
dependent  
continuous/inter
val/ratio 
QOL-PH at T1, 
T2, T3 
mixed linear 
models/Jonckh
eere-Terpstra 
5 Genetics 
descriptive 
statistics 
(frequencies) 
  
T1 = Time 1, T2 = Time 2, T3 = Time 3 
Data analysis.  Data was entered into SPSS® v.22, and double checked by two 
additional staff persons.  A master file copy was saved, and password protected as backup 
for the working file.  A working file copy was made to conduct the analysis.  
Additionally, initial checks for outliers and frequency distributions, boxplots, histograms 
and descriptive statistics were conducted.  Data analysis included the mixed linear model.  
This model is helpful to use with data such as is presented here, which has missing 
variables, and inconsistent group sizes (Field, 2013).  
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CHAPTER 4 
Results 
 The purpose of this dissertation study was to evaluate by provider types of care 
coordination, primary care and psychiatry, the change of depression severity (PHQ-9), 
depressive symptoms (QIDS-SR16) and quality of life (SF-36) over time (T1-T3) in a 
population of patients diagnosed with MDD or DDNOS after having had 
pharmacogenetic testing.  This chapter describes the data collection, cleaning, and 
analysis methods and results for each question. 
Review of Data Collection Procedure 
Summary of study procedures and study sample.  Data was collected from 
three ongoing studies of pharmacogenetics in depression.  All patients had a diagnosis of 
Major Depressive Disorder (MDD), or Depressive Disorder-  Not otherwise specified 
(DDNOS).  All participants completed the same questionnaires including the PHQ9 to 
measure depression severity, the QIDS-SR to measure depression symptoms, and the 
SF36 to measure quality of life.  
Each study sought to enroll 100 volunteers per provider type.  At the time of this 
analysis, 100 participants had not yet been achieved for each study.  Data collected 
through February 6, 2016, was combined to complete this analysis and included 
populations with the differing provider types of care coordination (n = 26), primary care 
(n = 38), and psychiatry (n = 54).  All participants were included in the analysis who had 
signed informed consent for their study regardless of how many visits the participants 
had completed.  Two of the studies, primary care and psychiatry, were randomized 
studies.  The study visits were standardized, so that regardless of randomization, the same 
time points were evaluated.  Evaluation of a baseline visit, the visit which the participant 
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received their pharmacogenetics report (PGXr) and one visit four weeks after receipt of 
the PGXr were collected for data analysis.  
 Data collection challenges included missed visits, due to patient non-compliance 
and missed visits related to the visit number which the participant was currently 
completing at the time the study closed enrollment.  Some participants were newly 
enrolled and only finished one visit while others had completed the entire study at the 
date of the data analysis.  
 Questionnaire data was manually entered into a Microsoft Excel spreadsheet for 
each study.  After manual entry, data was double-checked by an independent researcher.  
Data was source verified, de-identified and cleaned for analysis.  All data was password 
protected, and analysis was completed in SPSS® v. 22.  
Statistical Methods.  Descriptive statistics were implemented for data analysis of 
the populations.  These included frequency, means (M), standard deviations (SD), 
medians, and sample size counts.  This information was used to understand missing 
values, and distributions of the data.  T-tests were conducted for comparison of groups; 
Bonferroni corrections were made when multiple t-tests were completed. 
A mixed linear model was used to analyze the repeated measures of depression 
severity (PHQ9), depression symptoms (QIDS-SR16), and quality of life (SF36).  Mixed 
linear model was chosen over ANOVA for repeated measures because of the number of 
missing values, and missed visits (Bernstein et al., 2010).  Mixed linear models are more 
robust in analyzes when there are missed visits, which may interfere with sample size 
(Hardin & Hilbe, 2012; Heritier, 2009).  Mixed linear models provide information 
regarding the data in a multilevel evaluation of repeated measures such as are represented 
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in this study.  This model provided information regarding between and within group 
effects.  Schwarz’s Bayesian Criterion was evaluated for p values of each model selected.  
The validity of each model utilized having a p-value < .05, was tested against variations 
of the final statistical model.  To understand detailed trends and rank between groups and 
time periods for the quality of life criteria (SF36), the Jonckheere-Terpstra trend statistic, 
a non-parametric test, was used for the concepts included in the ‘mental composite 
scores’ (MCS) and ‘physical composite scores’ (Jonckheere, 1954) for more information 
regarding the subscale concepts, refer to the table (Table 5). 
Internal reliability for questionnaires 
 A Cronbach’s alpha was calculated for each questionnaire used for this study and 
showed good reliability as > 0.70 for all questionnaires used.  The PHQ9’s Cronbach’s 
alpha was .88, which was slightly higher than the reported .85 of previous studies.  The 
QIDS Cronbach’s alpha was .76, which was lower than previous reports of .88 -. 92.  The 
SF-36 has two measures, physical composite score (PCS) and mental composite scores 
(MCS), which were Cronbach’s alpha was .97 and .89 respectively.  The SF36 subscale 
Cronbach’s alpha for both primary scores of MCS, and PCS ranged from .79 to .94. The 
SF-36 internal reliability measures were similar to previously reported Cronbach’s 
alphas. 
Demographic results 
Sample Demographic results.  The sample population participated in three 
studies conducted in the upper Midwest.  The studies included patients who were referred 
by their providers including primary care, and psychiatric providers along with care 
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coordination referrals.  Tabular demographic results are represented (Table 8) and clinical 
demographics are also presented (Table 9). 
Table 8 
Demographic distribution   
  
n =   % 
Gender  
N = 124 
Male 31 24% 
Female 93 73% 
Ethnicity 
N = 117a 
Caucasian 115 90% 
Unknown 1 1% 
American 
Indian 1 1% 
Employment 
Status 
N = 124 
Employed 46 37% 
Unemployed 7 6% 
Retired 6 5% 
Disabled 10 7% 
Unknown 55 43% 
Marital Status 
N = 117a 
Single 39 32% 
Married 59 48% 
Divorced 16 13% 
Separated 0 0% 
Widowed 3 2% 
Insurance Type 
N = 124 
Private 83 65% 
Self-pay 4 2% 
Medicaid 37 30% 
Smoking status 
N = 121b 
Non-smoker 74 61% 
Current 
smoker 17 14% 
Former 
smoker 19 16% 
Unknown 11 9% 
a. Missing data (n = 7) N = 124. 
b. Missing data (n = 3) N = 124. 
 
The total sample size was N = 124, with ages ranging from 19 to 84 years old (M 
= 45, SD = 14.66).  The overall sample was Caucasian (90.3%) and female (73.4%).  In 
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addition, the majority of the population was employed (37.1%) with private insurance 
(65.3%), and fewer participants were unemployed (4.6%), retired (4.8%) or disabled 
(7.3%).  Similarly, fewer participants had Medicaid (29.8%) or were self-pay (2.4%).  
Most participants were married (47.6%) followed by less who were single (31.5%).  
There was a wide range (0-17) of number of chronic conditions.  
Table 9 
Total Sample Descriptive Statistics 
  N Minimum Maximum M SD 
Age 120 19 84 45.69 14.67 
Number of chronic 
illnesses 
118 0.00 17.00 4.37 3.90 
Number of mental 
health diagnoses 
118 1.00 6.00 2.08 1.18 
Number of medications 115 0 37 10.64 7.17 
 
Demographics based on provider type.  The demographics by provider 
included, care coordination (n = 24), primary care (n = 41), and psychiatry (n = 54).  The 
demographics information gathered during the study included: a) age b) gender c) 
primary health insurance d) marital status e) ethnicity, d) employment, e) number of 
chronic health conditions f) number of mental health conditions.  Primary health 
insurance was categorized as self-pay, Medicaid, or private insurance.  Employment was 
classified as employed, unemployed, disabled, retired or unknown.  Marital status was 
classified as single, married, divorced, separated, or widowed.  Clinical demographic 
descriptive statistics were conducted on these data (Table 9). 
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Table 10 
 
Demographics by provider type 
  
Sample Characteristic 
Care 
Coordination 
Primary 
Care 
Psychiatry 
Sample size  n = 26 n = 41 n = 54 
  % % % 
Gender Female 73.1 80.5 72.2 
 Male 26.9 19.5 27.8 
Ethnicity Caucasian 92.3 87.8 96.3 
 Unknown 3.8 12.2 3.7 
 
Native 
American 
3.8 0.0 0.0 
Insurance 
Type 
Private  30.8 75.6 77.8 
 Self-pay 3.8 0.0 3.7 
  Medicaid 65.4 24.4 18.5 
Employment 
Status 
Employed 38.5 26.8 46.3 
 Unemployed 3.8 9.8 3.7 
 Disabled 23.1 0.0 5.6 
 Unknown 34.6 61.0 35.2 
 Retired 0.0 2.4 9.3 
Marital 
Status 
Single 38.5 36.6 25.9 
 Married 42.3 51.2 46.3 
  Divorced 19.2 4.9 14.8 
  Widowed 0.0 2.4 3.7 
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Table 11 
 
Clinical demographics by provider type 
 
 
 
 
 
 
 
 
 
 
 
 
n = 4 missing data for age, n = 6 missing data for number of chronic illnesses and number 
of mental health diagnoses, n = 9 missing for number of medications.  N = 124  
 
Age.  Age was compared for three groups, care coordination, primary care and 
psychiatry.  Groups were similar p = 0.149, at a significance level of p = .05.  The mean 
age among groups, were care coordination (M = 50.38, SD = 11.19), psychiatry (M = 
44.61, SD = 15.62) and primary care (M = 44.10, SD = 15.01). 
Gender.  The total sample for all groups included 32 males and 94 females.  The 
proportions in gender between groups were similar; care Coordination (73.1%), primary 
care (80.5%) and psychiatry (72.2%).  
Insurance type.  Private insurance was the primary insurance type for both 
primary care and psychiatry (n = 31; n = 42).  Medicaid was the primary insurance type 
for care coordination with (n = 17). 
Marital status.  This study’s total population included the largest percent who 
were married (47.6%) over those who were single (31.5%).  Similarly, Table 10 shows 
that each group has a high number of married and single participants.  Care coordination, 
primary care, and psychiatry all had the high percentages of people whose status was 
 
Care 
coordination 
Primary Care Psychiatry 
 M (SD) M (SD) M (SD) 
Age  50.38 (11.19) 44.10 (15.01) 44.61(15.62) 
Number of chronic 
conditions 
 7 (3.5) 3.52 (4.17) 3.7 (3.32) 
Number of mental 
health diagnoses 
 2.15 (1.54) 2.12 (1.07) 2.0 (1.07) 
Number of 
Medications 
 15.04 (6.83) 8.62 (6.22) 
 
9.88 (7.16) 
 
82 
  
married, 42.3%, 51.2%, 46.3% respectively.  Care coordination had the highest 
percentage of divorced and single participants 19.2% and 38.5% respectively. 
Employment.  Primary care, care coordination and psychiatry groups had the 
following rates of employment, respectively from 26.8%, 38.5%, to 46.3%.  Care 
coordination had the highest percentage of disabled participants (23.1%), and psychiatry 
had the highest percentage of retired participants, 9.3%. 
Number of chronic conditions.  There was a difference (p < 0.001) in chronic 
physical conditions between care coordination, (M = 7.0, SD = 3.5), primary care (M = 
3.52, SD = 4.169) and psychiatry (M = 3.7, SD = 3.32). 
Number of mental health diagnoses.  There was no difference among groups for 
the number of mental health diagnoses (p = 0.801).   
Number of medications.  Care coordination patients were prescribed more 
medications than primary care (p = .001), and psychiatry groups (p = .006).  There was 
no difference between primary care and psychiatry groups (p = 1.00).  
Analysis of group for depression severity (PHQ-9) 
Table 12  
PHQ mean scores all patients 
Visit  n M SD 
95% Confidence Interval for 
Mean 
Lower Bound 
Upper 
Bound 
1.00 120 14.6000 5.50080 13.6057 15.5943 
2.00 99 11.7879 5.78223 10.6346 12.9411 
3.00 90 10.2444 6.26263 8.9328 11.5561 
Total 309 12.4304 6.08483 11.7493 13.1115 
 
 The mean depression severity scores decreased over time F (2, 303) = 15.3l, p = 
.001.  There was a decrease in score from visit one (M = 14.6, SD = 5.5) to visit two (M = 
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11.78, SD = 5.7), with a mean decrease M = -2.8, 95% CI [-4.7, -.91], which was 
statistically significant (p = .001).  Table 11 shows means and standard deviations for 
each visit.  There was not a significant decrease from visit two (M = 11.79, SD = 5.8) to 
visit three (M = 10.2, SD = 6.2) with a mean decrease M = -1.54, 95% CI [-3.6, .50], 
which was not statistically significant (p = .21).  The mean decrease from visit one to 
visit three was significant, M = -4.36, 95% CI [-6.31, -2.40], p < .05. 
Analysis of group for depression symptoms (QIDS) 
Table 13 
Mean scores for all participants QIDS  
Visit N M SD 
95% Confidence 
Interval for Mean 
Lower 
Bound 
Upper 
Bound 
1 121 13.10 4.52 12.28 13.91 
2 99 12.14 6.98 10.75 13.53 
3 92 9.62 5.15 8.55 10.69 
Total 312.00 11.77 5.75 11.13 12.41 
  
The mean depression symptom scores decreased over time F (2, 309) = 10.46, p < 
.001.  There was a decrease in mean score from visit one to visit two (Table 13).  
However, this did not represent a significant change, as represented by a mean decrease 
M = -.96, 95% CI [-2.8, .87], p = .62.  There was a decrease from visit two to visit three 
with a mean decrease M = -2.5, 95% CI [-4.5, -.57], p = .01).  The mean decrease from 
visit one to visit three was significant, M = -3.5, 95% CI [-5.3, -1.6], p = < .001. 
Analysis of group for QOL-physical composite scores 
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Table 14 
SF-36 Mean physical quality of life scores by visit-PCS  
Visit N M SD 
95% Confidence Interval 
for Mean 
Lower Bound 
Upper 
Bound 
1 119 43.96 12.36 41.72 46.20 
2 90 45.48 12.77 42.81 48.16 
3 92 45.75 12.20 43.22 48.27 
Total 301 44.96 12.42 43.55 46.37 
 
 There was not a change in physical quality of life F (2, 298) = .648, p = .52.  The 
means are represented at each visit (Table 12), and the change in means between visits 
(Table 14) are also represented.   
Table 15 
 SF-36 multiple comparisons of physical composite score by 
visit 
(I) VISIT 
M (mean 
difference) p  
95% Confidence 
Interval 
Lower Bound 
Upper 
Bound 
1 
2 -1.52 1.00 -5.71 2.66 
3 -1.79 0.91 -5.94 2.37 
2 
1 1.52 1.00 -2.66 5.71 
3 -0.26 1.00 -4.70 4.18 
3 
1 1.79 1.73 0.91 -2.37 
2 0.26 1.84 1.00 -4.18 
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Analysis of group for QOL-mental composite scores 
Table 16 
SF-36 mean scores by visit- Mental composite score 
 N M SD 
95% Confidence Interval 
for Mean 
Lower Bound 
Upper 
Bound 
1 119 29.97 11.21 27.93 32.00 
2 90 35.23 13.01 32.51 37.96 
3 92 36.97 12.15 34.46 39.49 
Total 301 33.68 12.41 32.28 35.09 
 
 There was an increase in quality of mental composite scores, F (2,298) = 9.8, p < 
.001. (Table 16).  A pairwise comparison indicates that there was an increase from visit 
one to visit two, M = 5.3, 95% CI [1.21, 9.3], p < .01 and between visits one and three, M 
= 7, 95% CI [ 2.97, 11.3], p < .001.  However, there was not a change between visit two 
and visit three, M = 1.74, 95% CI [-2.56, 6.04], p = .993. 
Research questions 
1.  Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in depression severity (PHQ9) over time (T1-T3) 
based on the type of provider?  
The statistical model for the PHQ9 included time and provider type as main effects 
and time and provider interactions (p < .05).  The interaction of provider type and time 
was significant for depression severity, F (2, 102.81) = 3.84, p = .024.  Pairwise 
comparisons indicate that care coordination patients had less severe depression severity, b 
= -2.501, t = -7.718, p < .001, than primary care and psychiatry patients.  In contrast, 
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there was no difference between PHQ9 scores for primary care and psychiatry in 
depression severity b = .499, t = .89, p = .373.  
a. Hypothesis 1: Depression severity scores (PHQ9) among patients who 
receive care coordination will decrease over time.  
This study found that PHQ9 mean scores (SD) decreased with each visit from 
visit one to visit three respectively, M = 10.52, SD = 6.85; M = 10.18, SD = 7.60; M = 
8.11, SD = 6.34.  However, this did not represent improvement, t = 1.195, p = .24.  This 
hypothesis was not supported.  Depression severity was represented as changes in 
patient’s depression severity of levels > 9 to levels < 9, indicating clinical improvements 
(Table 17) 
Table 17 
PHQ scores 
PHQ-9 (< 8) 
 Low Depression 
Severity 
PHQ-9 (≥ 9) 
High Depression 
 severity 
  Visit 1 Visit 2 Visit 3 Visit 1 Visit 2 Visit 3 
Overall Group n = 121       
Number of participants 44 80 94 77 41 27 
Percent of participants 36.36 66.12 77.69 63.64 33.88 22.31 
Care Coordination n = 26       
Number of participants 16 22 23 10 4 3 
Percent of participants 64.54 84.62 88.46 38.46 15.38 11.54 
Primary Care n = 41       
Number of participants 12 26 33 29 15 8 
Percent of participants 29.27 63.41 80.49 70.73 36.59 19.51 
Psychiatry n = 54       
Number of participants 16 32 38 38 22 16 
Percent of participants 29.63 59.26 70.37 70.37 40.74 29.63 
 
b. Hypothesis 2: Depression severity scores (PHQ9) among patients who 
receive care by a Primary care provider will decrease over time. 
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PHQ9 mean scores decreased with each visit from visit one to visit three, M = 
16.0, SD = 4.955; M = 13.73, SD = 5.11; M = 12.0, SD = 5.98.  These means indicate a 
decrease in depression, t = 2.874, p = .006.  Twenty-one participants (51%) who were 
being managed by primary care providers reduced their depression severity scores from 
being greater than 9 (moderate to severe) to less than 9 indicating a mild depression 
status (Table 16).  This hypothesis is supported. 
c. Hypothesis 3: Depression severity scores (PHQ9) among patients who 
receive care by a Psychiatrist will decrease over time.  
PHQ9 mean scores decreased with each visit from visit one to visit three, M = 15.42, 
SD = 4.25; M = 11.16, SD = 5.33; M = 10.2, SD = 6.22.  This indicates a decrease in 
depression severity from visit 1 to visit 3, t = 4.95, p < .000.  Twenty-two participants 
(41%), reduced their depression severity category by moving from having a score greater 
than nine at visit one to having a score less than nine at visit three.  This hypothesis is 
accepted. 
Table 18 
QIDS severity groups 
QIDS-SR (<10) 
Fewer symptoms 
QIDS-SR (≥11) 
More symptoms 
   Visit 1  Visit 2 Visit 3 Visit 1 Visit 2 Visit 3 
Overall Group       
Number of participants 48 73 92 73 48 29 
Percent of participants 39.67 60.33 76.03 60.33 39.67 23.97 
Care Coordination       
Number of participants 16 19 22 10 7 4 
Percent of participants 64.54 73.08 84.62 38.46 26.92 15.38 
Primary Care       
Number of participants 11 31 30 30 10 11 
Percent of participants 26.83 75.61 73.17 73.17 24.39 26.83 
Psychiatry        
Number of participants 21 23 40 33 31 14 
Percent of participants 38.89 42.59 74.07 61.11 57.41 25.93 
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2. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in depression symptoms (QIDS-SR16) over time 
(T1-T3) based on provider type? 
Table 19 
Type III Tests of Fixed Effects QIDS  
Source 
Numerator 
df 
Denominator 
df F p 
Provider 2 118.932 6.929 .001 
Visit 1 98.492 34.829 .000 
Provider * Visit 2 97.521 3.055 .052 
a. Dependent Variable: QIDS. 
 
The statistical model included interaction and main effects of provider type and visit 
for depression symptoms (QIDS) at the level of p < .05.  There was no interaction found 
between provider type and change over time for depression symptoms, F (2, 97.52) = 
3.05, p = .052.  There were main effects of visit and provider (Table 18).  The number of 
participants who moved from high levels of symptoms (QIDS >11) to low levels of 
symptoms (QIDS <11) are presented above (Table 17).  Clinically, this indicates that 
36% of patient’s symptoms improved from visit one to visit three (Table 17). 
a. Hypothesis 1: Depression symptom scores (QIDS-SR16) will decrease 
over time (T1-3) among patients who receive care coordination. 
For care coordination the mean scores declined from M = 10.5, SD = 4.14 at visit 
one to M = 9.0, SD = 3.56 at visit 3.  However, visit two increased to M = 11.6, SD = 
5.2.  Overall, this did not represent a decrease in symptoms, t = 1.19, df  = 15, p = .25.  
The hypothesis was not supported.  Clinically this represents a change from high 
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depression symptoms (QIDS > 11) to low depression symptoms (QIDS <11) for 23% of 
patients.  This does not support the hypothesis. 
b. Hypothesis 2: Depression symptoms scores (QIDS-SR16) will decrease 
over time (T1-T3) among patients who receive Primary care services. 
Visit one M = 14.8, SD = 4.72, decreased to M = 9.77, SD = 4.63 at visit two and 
then increased to M = 11.0, SD = 5.3 at visit three.  This represented a decrease in 
depression symptoms, t = 2.9, df = 24, p = .007.  Clinically this represented a change 
from high depression symptoms (QIDS >11) to low depression symptoms (QIDS< 11) 
for 46% of patients.  This supports the hypothesis. 
c. Hypothesis 3: Depression symptoms scores (QIDS-SR16) will decrease 
over time (T1-T3) among patients who receive care through psychiatry. 
The mean depression symptom scores decreased from visit one to visit three 
respectively, M = 13.1, SD = 4.0; M = 13.64, SD = 8.2; M = 9.1, SD = 5.5.  This 
represents a decline from baseline assessment to visit three, t = 5.8, df = 47, p = .000. 
Clinically this represent a change from high depression symptoms (QIDS >11) to low 
depression symptoms (QIDS< 11) for 35% of patients.  This supports the hypothesis. 
3. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in the physical composite score (physical 
functioning, role physical, bodily pain, general health) of the SF-36 scale by 
provider type? 
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Table 20 
Estimated Marginal Means for PCS by Provider 
Provider 
type M SD df 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Care 
Coordination 37.12 2.28 119.69 32.60 41.64 
Primary 
Care 46.10 1.79 120.60 42.56 49.64 
Psychiatric 
Care 47.11 1.56 117.34 44.02 50.20 
a. Dependent Variable: PCS. 
 
A one-way ANOVA indicates that care coordination patients had poor physical 
quality of life compared to both primary care F (2, 116) = 10.38, p = .000 and psychiatry 
patients, F (2, 89) = 4.38, p = .015.  There is no difference between primary care and 
psychiatry groups, with a mean difference of -1.1, SE = 2.39, p = .646.  
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Table 21 
 
 
 
 
 
 
 
 
 
 
 
 *significant difference found. 
a. Hypothesis 1: Overall physical composite scores (PCS) of the SF-36 scale will be 
highest in psychiatry and primary care, and lowest in care coordination.  
A pairwise comparison of the PCS scores per provider group was conducted using 
the Jonkheere-Terpstra trend statistic to determine trends over visits and between 
SF 36 Quality of life, comparison of visit and provider 
SF-36 
Concept 
Visit  
Care Coordination 
(CC) 
represented in means 
Primary Care 
(PC) 
represented in 
means 
Psychiatry 
(PS) 
represented 
in means 
PCS 1 35.02* 64.44 68.35 
  2 
No comparisons made, there were no differences found 
at this visit. 
  3 29.33* 48.93 51.74 
PF 1 39.02* 66.6 64.78 
 2 
No comparisons made, there were no differences found 
at this visit. 
 3 30.64* 50.77 50.11 
RP 1 & 2 
No comparisons made, there were no differences found 
at this visit. 
    
  3 35.92* 43.82 52.27 
BP 1 41.46* 62.15 67.08 
 2 
No comparisons made, there were no differences found 
at this visit. 
 3 31.69* 47.59 51.63 
GH 1-3 
No comparisons made, there were no differences found 
at this visit. 
MCS 1 91.96* 49.26 53.24 
 2 & 3 
No comparisons made, there were no differences found 
at this visit. 
   
VT   
There were no differences in VT, SF, RE at any visit. SF   
RE   
MH 1 86.24 54.06 52.22 
 2 &3 
No comparisons made, there were no differences found 
at this visit. 
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groups.  There was a difference found between groups at visit one, T JT = 2,595, z = 3.4, p 
= .001, and at visit three T JT = 1,656, z = 2.5, p = .01.  There were no differences found 
at visit two T JT = 1,425.5, z = 1.662, p = .09. and therefore no pairwise comparisons 
were completed (Table 21).  This hypothesis was supported. 
Table 22 
Pairwise comparison QOL PCS 
Visit Pairwise comparison Statistic 
1 
*CC < PC TJT = 763, z = 3.3, p = .000 
*CC < PS TJT = 1,036, z = 4, p = .000 
PS compared to PC TJT = 1,155, z = .522, p = .30 
2 No differences noted TJT = 1,425.5, z = 1.662, p = .09 
3 
*CC < PC TJT = 357, z = 44.4, p = .009 
*CC < PS TJT = 618, z = 3.05, p = .001 
PS compared to PC TJT = 618, z = .412, p = .32 
*indicates a difference 
CC = Care coordination 
PC = Primary care 
PS = psychiatry  
 
b. Hypothesis 2: When comparing by provider types, physical functioning 
scores in the SF-36 scale will be the highest in psychiatry and primary 
care and the lowest in care coordination. 
Physical function scores were different between provider groups at visit one T JT = 
2,743, z = 2.4, p = .02, and visit three T JT = 1,580.5, z = 2.0, p = .045, but not at visit 2, 
TJT = 1,419.5, z = 1.4, p = .150.  At visit one and visit three, care coordination had poorer 
physical functioning quality of life scores, indicating more difficulty with activities of 
daily living than primary care, and psychiatry groups (Table 21).  The hypothesis is 
supported. 
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Table 23 
Jonkheere-Terpstra trend statistic 
Pairwise comparison of the QOL- physical function 
Visit 
Pairwise 
comparison Statistic 
1 
*CC < PC T JT = 740.5, z = 3.0, p = .004 
*CC < PS T JT = 959, z = 3.2, p = .002 
PS = PC TJT = 1,043.5, z = -.329, p = .629 
2 No differences TJT = 1,419.5, z = 1.4, p = .150 
3 
*CC < PC TJT = 595, z = 2.7, p = .01 
*CC < PS TJT = 356.5, z = 2.36, p = .027 
PS = PC TJT = 629, z = 89.23, p = .567 
*indicates a difference 
CC = Care coordination 
PC = Primary care 
PS = psychiatry 
c. Hypothesis 3: When comparing by provider types Role Physical scores in 
the SF-36 scale will be highest in psychiatry, and primary care and lowest 
in care coordination. 
There were differences found between provider types at visit three T JT = 1,617, z = 
2.3, p = .023, but not at visit one T JT = 2,647, z = 1.9, p = .055, or visit two, TJT = 
1,368.5, z = 1.05, p = .294.  Care coordination had poor role-physical scores compared 
to psychiatry at visit two. (Table 22) for statistical pairwise comparisons.  The 
hypothesis was partially supported.  
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Table 24 
Jonkheere-Terpstra trend statistic, pairwise comparison of the QOL- role 
physical  
Visit 
Pairwise 
comparison Statistic 
1 
CC compared to PC T JT = 293.5, z = .938, p = .522 
*CC < PS T JT = 563, z = 2.4, p = .038 
PS compared to PC TJT = 760.5, z = 1.31, p = .286 
2 
No pairwise 
comparison T JT = 2,647, z = 1.9, p = .055 
3 
No pairwise 
comparison TJT = 1,368.5, z = 1.05, p = .294 
*indicates a difference 
CC = Care coordination 
PC = Primary care 
PS = psychiatry 
d. Hypothesis 4: When comparing by provider types Bodily pain scores in 
the SF-36 scale will be highest in psychiatry, and primary care and lowest 
in care coordination. 
  There were differences between provider types found at visit one T JT = 2,818.5, 
z = 2.8, p < .01 and visit three, T JT = 1,627.5, z = 2.4, p = .019.  Pairwise comparisons 
were completed for these visits (Table 23).  Care coordination patients had more severe 
pain than primary care and psychiatry.  The hypothesis is supported. 
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Table 25 
Jonkheere-Terpstra trend Statistic-Pairwise comparison of the QOL- 
Bodily Pain 
Visit 
Pairwise 
comparison Statistic 
1 
*CC < PC T JT = 694, z = 2.4, p = .024 
*CC < PS T JT = 944.5, z = 3.0 p = .004 
PS compared to PC TJT = 1,180, z = .717, p = .710 
2 
No pairwise 
comparison T JT = 2,647, z = 1.9, p = .055 
3 *CC < PS TJT = 599, z = 2.78, p = .008 
 CC compared to PC T JT = 333.5, z = 1.84, p = .098 
  PC compared to PS T JT = 695, z = .284, p = .851 
*indicates a difference 
CC = Care coordination 
PC = Primary care 
PS = psychiatry 
e. Hypothesis 5: When comparing by provider types, General Health scores 
in the SF-36 scale will be highest in psychiatry and Primary care and 
lowest in care coordination. 
There were no differences between provider type noted for any visit.  Visit one 
results are T JT = 2,469, z = 1.03, p = .303.  Visit two results are T JT = 1,329.5, z = 
.748, p = .455.  Visit three results are T JT = 1,455.5, z = 1.075, p = .282.  This 
hypothesis is not supported.  
4. Do patients with MDD or DDNOS who are participating in a pharmacogenetics 
testing study have differences in the mental components (vitality, social function, 
role emotion, and mental health) of the SF-36 scale by provider type? 
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Table 26 
Estimated Marginal Means for Mental Composite Score  
Provider type M SE df 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Care Coordination 
41.30 2.01 120.30 37.31 45.29 
Primary Care 
28.73 1.59 121.31 25.59 31.87 
Psychiatric Care 
33.33 1.35 111.14 30.65 36.01 
 
 Care coordination had better quality of life for their mental health than primary 
care or psychiatry patient’s F (2,118) = 12.01, p <. 001.  MCS was different at visit one T 
JT = 1,542.5, z = -3.56, p < .001. 
a. Hypothesis 1: When comparing by provider types, mental composite 
scores of the SF-36 scale will be highest in primary care and care 
coordination and lowest in psychiatry (Table 24).  
Care coordination had better mental health quality of life scores than primary care 
T JT = 152, z = -4.765, p <. .001, and psychiatry T JT = 224, z = -4.7, p < .001.  There were 
no differences between primary care and psychiatry, T JT = 1,166.5, z = .610, p = .729.  
This hypothesis was not supported. 
b. Hypothesis 2: When comparing by provider types, Vitality scores in the 
SF-36 scale will be the highest in primary care and care coordination and 
lowest in psychiatry. 
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There were no differences among provider types or visits for vitality scores.  
Therefore, there were no pairwise comparisons.  At all visits vitality did not differ, visit 
one, T JT = 1,999.5, z = -1.3, p = .19, visit two, T JT = 1,071, z = -1.23, p = .22 and at visit 
three T JT = 1,109, z = -1.49, p = .136.  This hypothesis was not supported.  
c. Hypothesis 3: When comparing by provider types, Social function scores 
in the SF-36 scale will be the highest in primary care and psychiatry and 
lowest in care coordination. 
There were no differences among provider types or visits.  Therefore, there were 
no pairwise comparisons.  At all visits social function did not differ, visit one, T JT = 
2,130, z = -.67, p = .51, visit two, T JT = 1,406.5, z = 1.35, p = .18 and at visit three T JT = 
1,432, z = .913, p = .361.  This hypothesis was not supported.  
d. Hypothesis 4: When comparing by provider types, Role Emotional scores 
in the SF-36 will be the highest in primary care and care coordination and 
lowest in psychiatry. 
There were no differences among provider types or visits.  Therefore, there were 
no pairwise comparisons.  At all visits role emotional scores did not differ, visit one, T JT 
= 2,010, z = -1.3, p = .21, visit two, T JT = 1,397, z = 1.3, p = .21 and at visit three T JT = 
1,397, z = 1.3, p = .205.  This hypothesis was not supported.  
e. Hypothesis 5: When comparing by provider types, Mental Health scores 
will be the highest in primary care and care coordination and lowest in 
psychiatry.  
There was a difference between providers at visit one, T JT = 1,572.5, z = -3.43, p = 
.001.  Care coordination had better mental quality of life than primary care T JT = 236, z 
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= -3.67, p < .001, and psychiatry T JT = 283, z = -4.1, p < .001. However, there was no 
difference found between primary care and psychiatry T JT = 1,053.5, z = -.25, p = .4. 
This hypothesis was not supported. 
5. How does the study population’s genetic phenotype (poor metabolizer, 
intermediate metabolizers, ultra-rapid metabolizer) in all provider types compare 
to the general population genetic phenotypical frequency rates?  
Table 27 
Comparison of Genetic phenotypes to Caucasian 
  
CYP 
2D6 
% 
CYP 
2B6 
% 
CYP 
2C9 
% 
CYP 
2C19 
% 
CYP 
1A2 
% 
CYP 
3A4 
% 
PM n = 13 n = 1 n = 1 n = 2 n = 2 n = 2 
study % 10.7 0.8 0.8 1.7 1.7 1.7 
Caucasian % 10  2 to 4 2 to 20   
EM n = 49 n = 41 n = 66 n = 47 n = 109 n = 103 
study % 40.5 33.9 54.5 38.8 90.1 85.1 
Caucasian % 48  60 14 to 44   
IM n = 30 n = 25 n = 16 n = 28 n = 2 n = 1 
study % 24.8 20.7 13.2 23.1 1.7 0.8 
Caucasian % 35  35 24 to 36   
IM^ n = 25 n = 43 n = 32 n = 2 n = 3 n = 10 
study % 20.7 35.5 26.4 1.7 2.7 8.3 
UR n = 0 n = 0 n = 1 n = 37 n = 0 n = 0 
study % 0 0 0.8 30.6 0 0 
Caucasian % 0 0 0 30 0 0 
 PM (poor metabolizer), EM (extensive metabolizer), IM (intermediate metabolism), IM^ 
(Intermediate metabolism clinical indication), UR (ultra-rapid metabolism). 
 For allelic distributions refer to Appendix H (Tables 26 – 31).  Genetic results of 
the sample, mimic the Caucasian population (Table 26).  
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Additional Analysis 
As a secondary analysis, not included in the research questions, an evaluation of 
the “acknowledgment form” was conducted.  This form was described in previous 
chapters and is listed in Appendix A.  This form was given to all providers with the 
PGXr.  Providers were instructed to return the form indicating a ‘yes’ or ‘no’ response to 
any medications changed because of the PGXr. In addition, they were asked if the patient 
acknowledged that the medication changes were based on the PGXr, and another ‘yes’ 
and ‘no’ response.  This yes or no acknowledgement was added to the mixed linear 
model as a covariant for the study.  Participants who had providers return the form were 
included in the analysis.   
All participants with missing documents were excluded from this analysis, so the 
total sample for each group included 22 care coordination patients, 29 primary care 
patients, and 49 psychiatry patients.  A summary of the breakdown of yes and no 
responses by provider group is below (Table 28).   
Table 28 
Providers indicating no or yes to acknowledgement form 
  No percent Yes percent 
Care coordination 2 7.7 20 76.9 
Primary care 10 24.4 19 46.3 
Psychiatry  26 48.1 23 42.6 
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A comparison of patients who received responses for the acknowledgement form and 
those who did not had results as listed in the following tables (Table 29-32). 
Table 29 
Depression severity (PHQ9) interaction with acknowledgment by group 
Parameter df t Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
Care coordination with 
yes response 
99.615 -4.399 .000* -9.293293 -3.515749 
Care coordination with 
no response] 97.820 -1.158 .250 -11.013160 2.898428 
Primary care with no 
response 91.824 -.353 .725 -4.051406 2.827432 
Primary care with yes 
response 93.473 .503 .616 -2.111065 3.544942 
Psychiatry group with 
yes response 87.831 15.830 .000* 13.108840 16.872816 
Psychiatry group with 
'NO' response 88.643 -1.438 .154 -4.461598 .714919 
*significant finding 
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Table 30 
QIDS and acknowledgment       
  
Estimate 
Std. 
Error df t Sig. 
95% 
Confidence 
Interval 
 
Lower 
Bound 
Upper 
Bound 
Care coordination 
"No' 
acknowledgement 
-.54 2.65 192.82 -.20 .84 -5.78 4.69 
Care coordination 
'yes' 
acknowledgement 
-1.97 .99 231.58 -1.97 .049* -3.94 -.007 
Primary Care 'No' 
acknowledgement 
.11 1.29 227.69 .09 .93 -2.43 2.66 
Primary care 
'Yes' 
acknowledgment 
.74 .99 237.43 .75 .46 -1.21 2.69 
Psychiatry 'NO' 
acknowledgement 
-.34 .90 243.94 -.38 .70 -2.12 1.43 
Psychiatry 'Yes' 
acknowledgement 
12.02 .65 245.62 18.3 .000* 10.72 13.30 
*indicates significant result 
Table 31 
Mental Composite Scores and acknowledgement 
Parameter df t Sig. 
95% Confidence Interval 
Lower 
Bound 
Upper 
Bound 
      
Care coordination ‘Yes” 
response 97.63 2.025 .046* .29 28.64 
Care coordination “no’ 
response 
96.96 2.71 .008* 2.16 14.03 
Primary care ‘no’ response 94.68 -.68 .49 -9.70 4.7 
Primary care ‘yes’ response] 96.24 -1.50 .13 -10.57 1.45 
Psychiatry ‘no’ response 
 
95.06 -.17 .86 -5.94 4.97 
Psychiatry ‘yes’ response 96.84 19.41 .000* 40.15 49.29 
*indicates significant findings 
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Table 32 
Physical composite score interaction with acknowledgment 
Parameter df t Sig. 
95% Confidence 
Interval 
Lower 
Bound 
Upper 
Bound 
Care coordination ‘no’ 
response 
94.614 -.904 .369 
-
23.417909 
8.768762 
Care coordination ‘yes’ 
response 
96.993 -2.744 .007* 
-
16.191572 
-2.599955 
Primary care ‘no’ 
response 
97.516 1.042 .300 -3.947478 12.678172 
Primary care ‘yes’ 
response 
98.018 1.132 .260 -2.970266 10.858393 
Psychiatry ‘no’ response 96.534 .465 .643 -4.801860 7.738867 
Psychiatry ‘yes’ response 96.844 19.421 .000* 40.146671 49.286616 
 
 When the statistical model was conducted, some interesting interactions were 
found regarding the change in depression severity scores.  Both the care coordination 
group (b = -6.40, t = -4.399, p <.0001) and the psychiatry groups (b = 14.99, t = 15.83, p 
<.0001) who had ‘yes’ responses to the acknowledgment of medication change had 
interaction for changes in depression severity of provider type, and acknowledgment.  
Primary care patients had no interaction.  Also, these two groups had interactions of  
physical and mental composite scores (Table 30 and 31).  This model takes into 
consideration change over visits for depression severity, study provider, and 
acknowledgment status. 
 This chapter has presented the results of this study, and a discussion of the major 
findings will follow in chapter 5.  This study was conducted to evaluate by provider type 
including care coordination, primary care and psychiatry, the change of depression 
(PHQ-9), depressive symptoms (QIDS-SR16) and quality of life (SF36) over time in a 
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population of patients diagnosed with MDD or DDNOS while participating in a study for 
pharmacogenetics testing.  This chapter presented the quantitative results using mixed 
linear models, Jonkheere-Terpstra trend statistics, one-way ANOVA, frequencies, and 
used descriptive statistics to answer the research questions presented in chapter 3.  
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CHAPTER 5 
Discussion 
 This Chapter discusses the results of the findings.  Strengths and limitations of the 
combined data set are discussed.  Additionally, clinical implications will be considered 
with recommendations for future research. The study was conducted to evaluate by 
provider type including care coordination, primary care and psychiatry, the change of 
depression (PHQ-9), depressive symptoms (QIDS-SR16) and quality of life (SF36) over 
time in a population of patients diagnosed with MDD or DDNOS while participating in a 
study for pharmacogenetics testing 
Participant Demographics 
There was no difference between the three groups regarding age or gender 
proportions.  However, this study had slightly more females than males and more females 
than other studies of depression.  An evaluation of insurance type showed that most of 
primary care and psychiatry had private insurance, while care coordination participants 
mostly had Medicaid, which was indicative of the population.  
Most of the participants were married or single, but care coordination, had a 
higher percentage of divorced patients and most resembled other studies of depression.  
Primary care had the lowest percentage of participants who were employed, and 
psychiatry patients had the highest percentage who were employed.  Care coordination 
had the highest percentage of disabled participants, and psychiatry had the highest 
percentage of retired participants.  Care coordination is a program that is offered to 
patients who are Medicaid or Medicare, who meet specific criteria for physical and 
mental illness, so this difference is not unexpected.   
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Care coordination had twice as many chronic health conditions and twice the 
number of medications than both primary care and psychiatry groups.  It is possible that 
care coordination participants had a decreased emphasis on mental health because of 
physical health complications.  More medication use can also complicate prescribing for 
depression and affect medication pharmacokinetics and thus effectiveness. 
Primary care and psychiatry studies controlled for mental health conditions.  Care 
coordination did not control for other mental health conditions, allowing for mental 
health comorbidities.  Interestingly, there was no difference between groups concerning 
number of mental health conditions.  
Discussion of Research Questions 
 Overall group changes.  All patients together, regardless of group, showed a 
decrease in depression severity, depression symptoms and an increase of mental 
composite quality of life from visit one to visit three.  Participants baseline scores started 
at high moderate and decreased to the low moderate level at visit three for depression 
severity.  The decrease in symptoms indicated a change from moderate symptoms at 
baseline to minimal at the third visit.  This decrease in depression severity and symptoms 
also resulted in an improvement in mental quality of life. But, quality of life reveals no 
change in physical composite scores.  Overall, patients who were receiving treatment 
through the study improved for all measures, excluding physical composite scores.  
Primary care and psychiatry groups had higher numbers of participants which may have 
influenced these total sample results. Care coordination had the fewest number of 
participants and therefore the smallest impact on overall changes for the group as a 
whole.  
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 Depression severity (PHQ9). 
The objective for this study was to evaluate differences in depression severity 
between groups. Results indicate that care coordination was less depressed and had lower 
depression severity, than primary care and psychiatry patients.  Level of depression was 
similar between primary care and psychiatry patients.  Additional analysis assessed 
change over time in each provider group.  Because participants in care coordination are 
complex patients, there was a question about the inability of patients to decrease 
depression severity during the three time points, and this proved true.  Care coordination 
did not improve their depression severity over time.  However, care coordination 
participants had low moderate levels of depression to begin the study, and improvements 
from that level of depression may take more time and higher sample size to see statistical 
improvements. On the other hand, this may be representative of fluctuations within a 
chronic underlying depression that is comorbid with chronic illness.   
Primary care and care coordination participants had decreases in their depression 
severity from baseline to time three.  About fifty percent of participants in both groups 
were able to reduce their depression from baseline levels of moderate to severe 
depression to mild depression category.  This is a clinically important point for this study, 
suggesting that primary care providers are as effective as psychiatrists in managing 
depression severity.    
The conclusions for depression severity in this study are consistent with previous 
studies, such that primary care and psychiatry patients tended to have similar depression 
severities.  Primary care and psychiatry levels were in the severe depression range.  There 
were decreases in both primary care and psychiatry in depression severity scores over the 
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course of three visits, but no change in care coordination.  Mostly likely, this lack of 
change is a reflection of the lower baseline scores in the care coordination group, and that 
there were no inclusion criteria to control for higher depression rates.  
Depression symptoms (QIDS). 
There was no interaction between provider type, change over time and depression 
symptoms.  However, it is interesting that compared to an analysis of combined 
participants which indicated improvements in symptoms, the individual provider groups 
did not all show decreases.  Care coordination participants did not have decreases in 
symptoms, which was probably attributed to health problems which potentially interfered 
with the patient’s ability to separate depression related symptoms from illness related 
symptoms.   
Both primary care and psychiatry participants had decreases in their depression 
symptoms.  This finding suggests that those who see primary care providers, but are not 
part of the care coordination program are able to discern differences in depression 
symptoms compared to chronic illnesses. While not measured, another possible factor is 
that they had higher health literacy.  Participants mean symptoms at baseline were higher 
in primary care than psychiatry patients, but not significantly so.  This finding may lend 
validation to previous studies which indicate more somatic complaints noted in primary 
care than psychiatric patients.  Mean symptoms were also consistent with previous 
studies conducted. 
Quality of Life (SF36) 
Physical Composite Score. The SF-36 instrument assesses physical quality of 
life and mental quality of life as two main scores.  Low scores on the quality of life scale 
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indicate poor quality of life while high scores indicate better quality of life.  The care 
coordination group had poor physical quality of life, in ‘physical composite scores’, 
‘physical function’ scores, ‘role physical’ scores, and ‘bodily pain’ scores, compared to 
the primary care and psychiatry groups.  Having low scores at most of the visits for care 
coordination patients indicates poor daily physical function.  Patients in care coordination 
tend to have more chronic conditions, some of which are pain related. Previous literature 
as discussed in chapter three, indicates that depression contributes to increasing disability 
with activities of daily living when a physical impairment also exists. Previous studies 
have reported that primary care patients had more impaired quality of life over psychiatry 
patients.  Our sample shows that primary care and psychiatry patients are similar in 
physical function with little problems in completing tasks of daily physical life.   
Interestingly, there were no differences in patient’s self-evaluation of ‘general 
health’ among provider types.  General health measures on the quality of life indicate 
one’s outlook on their future health.  This indicates that all patients had a similar outlook 
on their future health.   
Care coordination patients had higher ‘mental composite score’s than primary 
care and psychiatry patients.  This was an unexpected finding as the components of the 
‘mental composite score’ include the four subscales of ‘vitality’, ‘social function’, ‘role 
emotion’ and ‘mental health’.  The only subscale differences noted for mental composite 
scores between provider types were the overall ‘mental composite score’ and ‘mental 
health score.' Primary care and psychiatry groups had lower ‘mental composite scores’ 
indicating higher levels of stress and depression-related social disabilities than the care 
coordination group.  Also, primary care and psychiatry patients had poor ‘mental health 
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scores’, which indicates a more persistent and sustained depression.  In these two areas, 
care coordination patients had a better quality of mental health than either primary care or 
psychiatry patients.  Again, this may be related to primary care and psychiatry groups 
having higher PHQ9 scores at study entry, which signifies higher levels of depression.  
Primary care patients and psychiatry patients tended to have poor quality of life, and high 
levels of depression.  This combination of depression and quality of life is similar to 
previous studies.   
This study found that the care coordination group differed from both primary care 
and psychiatry groups for depression severity PHQ9, and SF36.  Interestingly, care 
coordination patients had less severe depression and high quality of life scores, indicating 
a good quality of life.  Studies of depression that also evaluated the quality of life 
reported that those with more severe levels of depression had a poor self-reported quality 
of life measurement.  The fact that quality of life scores were higher in care coordination 
patients, could be explained by the differing inclusion criteria.  The care coordination 
group did not have a baseline depression score restriction of ≥ 10 while primary care and 
care coordination did have this limitation.   
Pharmacogenetic phenotypes.  Pharmacogenetics testing was completed on 
most of the participants, with a pharmacogenetic guidance report (PGXr) conducted by 
genetic pharmacists for the study sample.  The genetic data was collected for the three 
individual studies but were combined for this study.  This study reported the frequency of 
phenotypes as they relate to the general population.   
All three studies had a pharmacogenetics component, and this question was 
simply to describe our study sample.  Reported genetic phenotypes were very similar to a 
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general Caucasian population, which means that this study may be generalized to a larger 
population of Caucasians.  There was initially speculation that because patients in care 
coordination had such complex medical conditions paired with large numbers of 
medications, that perhaps this study sample may have a higher incidence of genetics 
related to poor enzyme function in the liver to metabolize medications appropriately.  
However, results were similar to reported population averages.   
Acknowledgement forms 
 Response to the acknowledgment forms was highest for care coordination and 
lowest for primary care. Both the care coordination and psychiatry groups had 
improvements in depression severity and symptoms in those patients who the provider 
returned the acknowledgment form with a “yes” as opposed to a “no” response. 
Interestingly, care coordination did not have a significant decrease of depression related 
symptoms overall. This may be for several reason including the possibility that provider 
engagement, or medication changes based on pharmacogenetics was a mediator to 
change.  
When PCS and MCS for the quality of life measures were evaluated, care 
coordination patients showed an interaction of provider type and PGXr acknowledgement 
either way, ‘yes’ or ‘no’, for MCS.  Both yes and no acknowledgement were significant.  
This finding may be because there was a small sample size and small change in MCS or 
related to contact with care coordination.  The psychiatry group had an interaction as 
well, but only for those who answered ‘yes’ to the acknowledgement. Primary care 
showed no interactions.   
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In addition, care coordination and psychiatry groups also had significant changes 
for PCS for those whose provider returned the form with a “yes”.  Primary care again had 
no change.  It is easy to suspect that there were changes in physical quality of life in the 
care coordination patients because this sample of patients scored very low in this 
category, and any improvement could be noteworthy.  In addition, if medications were 
made based on the PGXr with the patient’s acknowledgment the patient could have a 
sense of improvement.  It is unclear, however, this author speculates that patients were 
more engaged by the research team and residents regarding changes that occurred in 
psychiatry.  
The PGXr acknowledgement form and process results need more clarification and 
study.  It is unclear if the form is a good indication of patient understanding and 
acknowledgment to medication changes based on pharmacogenetics because it was a 
provider form.  Patients did not fill out the form and return.  A more controlled study, 
with a questionnaire related to patient acknowledgement of and understanding of changes 
made because of pharmacogenetics would have better validity.  However, the finding 
suggest that care coordination was more aware of the processes, and changes based on 
this study’s findings.  This conclusion, however, must be viewed with caution based on 
these results.   Evaluation of patient’s awareness of the pharmacogenetics 
processcertainly needs future more controlled study.   
Nursing Theory relationship 
 Dorothea Orem’s SCDT explains factors that specifically relate to the care 
coordination participants.  For example, three perspectives contribute to self-care, 
conditioning factors, psychophysiological factors of health and disease and behavioral 
112 
  
resources and demands.  The care coordination participants had a combination of 
physical and mental health needs, and many were lacking resources.  Some care 
coordination participants were homeless, lacked financial resources and had limited 
health literacy.  Nursing guidance is important when patients have low health literacy to 
help guide patients in, for example, behavioral changes and understanding medications.  
The lack of health literacy, lack of financial resources and physical complication to basic 
everyday activities, can cause deficits in self-care abilities and these are evident in the 
low physical composite scores noted in the care coordination group compared to the 
primary care and psychiatry group.  These deficits may be filled by nursing resources and 
programs such as care coordination and care transitions programs.  
 The deficits noted in the quality of life for the physical component in care 
coordination reflect lack of self-care agency.  Self-care agency is the power and ability to 
care for oneself.  Patients in the care coordination group had worse physical scores in 
‘role-physical’ and ‘physical function’ on the quality of life measure.  ‘Role physical’ 
indicates deficiencies at work or with employment due to the interference of physical 
problems.  In addition, ‘physical function’ is a limitation of daily activities of living.  The 
care coordination group had the highest percentage of physically disabled and 
unemployed participants, which is evidenced in the physical quality of life total score and 
sub-scale scores.  These indicators of quality of life reflect a need for nursing 
intervention.   
Strengths of the study. 
 This study had several strengths such as similarities in study design between the 
three samples, use of the same questionnaires and similarities of visit timelines. Having 
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care coordination as a group comparison added more information to previously published 
literature and filled the literature gap.  The willingness of providers and nursing staff to 
assist with this study also was a strength for data collection and the reduction of patients 
becoming lost-to-follow-up. 
 This study added a unique picture of depression in three unique samples.  
Evaluation of primary care and psychiatry patient’s depression has been previously 
researched. The addition of care coordination with this the population’s physical 
limitations, low health literacy, high health care utilization and health complexities added 
an interesting perspective to the comparison.  
Challenges and Limitations 
There were multiple challenges and limitations beginning with enrollment. When 
the three studies were designed, it was predicted that the care coordination study would 
complete enrollment quickly.  However, protocol inclusion criteria which restricted 
insurance type limited the sample size; therefore, an amendment was completed. While 
recruitment increased, the process was slow and numbers remained low for care 
coordination.  The primary care group had no research coordinator at the clinics to guide 
the research process, so enrollment and follow-up visits were completed over the phone 
and through the mail. This process increased the number of missed or delayed visits.  The 
psychiatry group had the highest enrollment number as the study was overseen by 
medical residents and research staff Psychiatry also had the fewest missed visits and 
patients lost to follow-up.   At the time the analysis was completed, participants were at 
various stages of the study and contributed to missed visits and incomplete data 
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collection. Missing data can be a significant problem associated with increasing bias, and 
creating issues with sample size.   
 Self-report measures are also a limitation in survey research because the 
researcher must rely on a patient’s ability to be introspective and truthful about one’s 
condition.  Some problems may occur because participants were unwilling to answer 
certain questions or avoided truthful responses. Additionally, the patient answered the 
same questionnaires multiple times, which may have caused the patient to anticipate 
questions and report on them differently.  Furthermore, the choice of participating clinics 
for all provider types, care coordination, primary care, and psychiatry was limited to a 
convenience sample of within-health system participation. The lack of randomization can 
lead to biased results..   
 Additionally, the purpose of the care coordination study was not originally to 
make a comparison between groups, and so the depression severity inclusion criteria 
were slightly different than the primary care and psychiatry studies.  This had a potential 
influence on the outcomes noted for care coordination.  Along with this difference, the 
care coordination participants had restrictions on the type of insurance that the patient 
could have to enter the study. 
Future Implications.  Future study recommendations include the addition of the 
patient activation measure (PAM), to fully understand how engaged the care coordination 
patient is compared to primary care or psychiatry.  Using a measure of patient activation 
may offer data and insight on components associated with self-care activities.   
This study evaluated overall numbers of symptoms using the QIDS self-report 
form.  However, an evaluation of the types of symptoms experienced overall and between 
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each group may shed more light on the care coordination group’s differences.  
Additionally, an understanding of depression symptoms and which specific symptoms 
were reduced may be important to understand the overall effect and impact on patients.  
Other studies found that most people experienced sexual side effects when on 
antidepressant medication.  This analysis was not completed with this study but will be 
conducted later.   
Cost outcomes are an important measure of clinical use.  Does pharmacogenetics 
testing improve future cost expenses to patients and health systems? This has yet to be 
addressed.  The centers for Medicare and Medicaid, are reimbursing some 
pharmacogenetics testing such as for clopidogrel, an antiplatelet medication, which has 
been shown to have clinical utility and decreases costly health and economic outcomes 
for both patients and hospital systems.  However, reimbursements are few and far 
between for other indications such as in mental health applications.   
Nursing influence on outcome was not the primary goal of this study; however, 
this study contributes to baseline understanding of depression in the care coordination 
sample compared to primary care and specialty care settings.  Future studies are needed 
to understand nursing’s influence for improving outcomes for patients with depression 
through participating in care management or care coordination.  This study shows that the 
care coordination participants are a unique study sample with individualized needs which 
can be met with patient centered-care coordination.  This study speaks directly the care 
coordination competencies and nursing’s ability to provide care for those in self-care 
deficit.  
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Summary 
 This study evaluated differences in depression severity (PHQ9), depression 
symptoms (QIDS), and quality of life (SF36) in three populations of patients being 
treated by different providers.  The three providers included care coordination, primary 
care and psychiatry.  The study compared patients from three provider groups who all 
had major depression disorder, or depression diagnosis-not otherwise specified.  All three 
studies used the same questionnaires at the same intervals, PHQ9, QIDS, and the SF36. 
 Care coordination was different from primary care and psychiatry on many levels. 
There were no inclusion criteria to control for baseline depression severity levels and 
mental composite quality of health which revealed that care coordination participants 
have lower depression severity compared to the other groups. This finding suggesting   
that care coordination’s depression is not as severe as primary care or psychiatry patients 
should be taken with caution since primary care and psychiatry inclusion criteria dictated 
higher levels of depression for all participants.  Care coordination group’s mental quality 
of health is also much better than the other groups. Care coordination group had more 
chronic illness and may be related to secondary depression caused by chronic illness. It 
was clear that care coordination participants had more chronic conditions and more 
complex situations because they also had the highest number of chronic diagnoses and 
highest number of medications compared to primary care and psychiatry patients.  
Overall, the chronic conditions found in care coordination appear to contribute to the 
mild to moderate depression found in this population.  
 Care coordination was had less depression severity and less symptoms but better 
mental quality of life than primary care and psychiatry patients. In addition, care 
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coordination had more chronic conditions and polypharmacy use, which was reflected in 
their poor quality of physical health scores.  However, there were parallels found between 
primary care and psychiatry patients. Primary care and psychiatry patients had similar 
depression severity, similar depression symptoms and similar quality of life scores for 
both physical and mental composite scores.  Depression in the primary care population 
has been studied as previously discussed in the literature review, and it has been 
identified as having more somatic symptoms than patients in psychiatry.  This finding 
was not supported in this study, however, given a larger sample size, perhaps this would 
have been the case.  Overall, the similarities between primary care and psychiatry 
patients was consistent with previous studies. 
Conclusion 
This study illustrates differences in care models which have the potential to 
influence patient depression outcomes and that primary care and psychiatry patients 
follow similar trends and characteristics.  Pharmacogenetic care may influence patient’s 
engagement, decrease depression severity and symptoms and improve quality of life. 
Care coordination patients differ from primary care and psychiatry patients in depression 
severity, depression symptoms and physical quality of life.  At its most elemental, this 
study has shown that care coordination participants have unique challenges and some 
advantages over primary care and psychiatry patients.  Care coordination participants 
have multiple challenges, because they have complex chronic illness in combination with 
mental health issues preventing or hindering activities of daily living.  The strengths of 
care coordination are the nursing leaders along with social workers who guide 
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participants care, strengthen the process of transitions, and navigation of the complex 
system of healthcare we have today  
Additional strengths for the care coordination group are that they had less 
depression and higher quality of life.  Previous studies directed attention toward managed 
care which might increase follow-through for patients and potentially better outcomes.  
Nursing is situated to make a large impact on the possible outcomes for depressed 
persons through care coordination.  Additional nursing interventions in all three settings 
would impact depression care and patient outcomes. 
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Appendix A 
Acknowledgment form 
 
PGX-TIME STUDY 
Psychotropic Genotyping panel research study 
Physician RESPONSE TO GENOTYPING PANEL report 
Patient Name____________________________________    DOB:___________________ 
Physician Response Plan as a result of the Psychotropic Genotyping Panel for research study. 
_________No medication changes planned 
_________Change in medication: 
  Current Medication:____________________________________ 
  New Medication:_______________________________________ 
________Change in Medication DOSAGE: 
  Current Medication/DOSE_______________________________ 
  New dosage:__________________________________________ 
Patient acknowledges medication change plans based on pharmacogenetic testing: 
__________Yes 
__________No 
Date:________________ 
Physician Referring Patient to Study:_______________________________ 
Staff completing form:___________________________________________ 
Phone:________________________ Email______________________________ 
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Appendix B 
Pharmacogenetic resources 
 
Resources for Clinical Guidelines in Pharmacogenetics Information available 
www.pharmgkb.org CPIC guidelines, DPGW 
http://medicine.iupui.edu/clinpharm/ddis/main-table/ CYP 450 pathways 
https://pharmacogenomics.ucsd.edu/ 
pharmacogenomics 
education 
http://www.nhlbi.nih.gov/research/resources/genetics-
genomics/pgrn Pharmacogenomics at NIH 
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Appendix C 
Pharmacogenetic CYP substrate pathways of Antipyschotics 
  
1A2 2B6 2C9 2C19 2D6 3A4,5,7 
amitriptyline 
(Elavil®) 
paroxetin
e 
(Paxil®) 
amitriptylin
e (Elavil®) 
amitriptyline 
(Elavil®) 
fluvoxamine 
(Luvox®) 
alprazolam 
(Xanax®) 
fluvoxamine 
(Luvox®)   
fluoxetine 
(Prozac®) 
escitalopram 
(Lexapro®) 
amitriptyline 
(Elavil®) 
diazepam 
(Valium®) 
asenapine 
(Saphris®)     
Citalopram 
(Celexa®) 
clomipramin
e 
(Anafranil®) 
midazolam 
(Versed®) 
olanzapine 
(Zyprexa®)       
Desipramine 
(Norpramin) 
triazolam 
(Halcion®) 
clozapine 
(Clozaril®)     
CYP 2D6 
(cont) 
doxepin 
(Silenor®)  (SSRI) 
pimozide 
(Orap®)     
haloperidol 
(Haldol®) 
trimipramine 
(Surmontil) 
vortioxetine 
(Brintellix) 
Thiothixene 
(Navane®)     
perphenazine 
(Prolixin®) 
amoxapine 
(Ascendin®) 
vilazodone 
(Biibryd®) 
trifluoperazin
e 
(Stelazine®)     
risperidone 
(Risperdal®) 
imipramine 
(Tofranil®) 
escitalopra
m 
(Lexapro®) 
      
thioridazine 
(Mellaril®) 
fluoxetine 
(Prozac®) 
Citalopram 
(Celexa®) 
      
zuclopenthixol 
(Clopixol®) 
nortriptyline 
(Pamelor®) 
lurasidone 
(Latuda®) 
      
iloperidone 
(Fanapt®) 
protriptyline 
(Vivactil®) 
aripiprazole 
(Abilify®) 
      
aripiprazole 
(Abilify®) 
paroxetine 
(Paxil®)   
      
quetiapine 
(Seroquel®)    
      
chlorpromazin
e 
(Thorazine®)    
Bohlen, Mattheissenn, Weisser,  2014. Avera Institute for Human Genetics 
psychotropic panel, unpublished 
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APPENDIX D 
Institutional Review Board Documents 
 
March 30, 2015 
 
Julie Kittelsrud, CNP Avera 
Research Institute 2020 S. Norton 
Avenue Sioux Falls SD 57015 
 
Dear Ms. Kittelsrud: 
 
Regarding Our Study # 2014.079 
Protocol Title: Evaluation ofPharmacogenetic (PGX Testing in a Mental health 
population and Economic Outcomes (PGX-Time) 
 
This is to inform you that the Avera IRB has reviewed your request regarding the 
above referenced research study.  This is to confirm that I have approved your 
request. 
Our Internal Number: 7770 
The following items were reviewed 
• Protocol Amendment 2, dated 24-Mar-2015 
• Patient Schedule of Participation, Amendment 2, dated 25-Mar-2015 
• MMAS-8 Coding Questionnaire 
• PAM-MH Questionnaire 
 
The study is subject to continuing review on or before 1/21/2016. You are reminded 
that you are required to report any serious reactions to the Avera Institutional 
Review Board within ten (10) business days of it occurrence (or your knowledge 
thereof). 
 
Please note that changes to the study as approved must be promptly reported 
and approved. Some changes may be approved by expedited review; others 
require full Committee review. Contact the Avera Institutional Review Board, at 
(605) 322-4755, if you have any questions or require further information 
regarding this IRB Action. 
 
 
 
Respectfully yours, 
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APPENDIX D 
Matthew Stanley, D.O. 
AMG University Psychiatry associates 4400 W. 69th Street 
Sioux Falls SD 57108 
 
RE:  Our Study #2014.081 
Dear Dr. Stanley: 
Meeting Date: 12/17/2015 
Protocol Title: Pharmacogenetic testing in an outpatient population of patients with 
Major Depressive Disorder or Depressive Disorder not otherwise specified with Avera 
University Psychiatry Associates. 
 
 
This is to inform you the Avera IRB renewed its approval of the above research study. The 
renewal is granted for an additional 12 months. 
 
The Effective date of the renewal is 12/17/2015: The approval period will expire on 
12/16/2016 
The following items were reviewed: 
• Continuing Review Report dated 3-Dec-2015 
• Informed Consent dated 23-Jan-2015 
 
All conditions for continued approval during the prior approval period remain in 
effect. These include, but are not necessarily limited to the following requirements: 
• A stamped copy of the most current Informed Consent Document (as noted 
above) is included. No other consent documents should be used. Each subject must 
sign the approved ICD prior to initiation of any protocol procedures. The original 
signed informed consent document must be placed in each subject’s 
medical/research chart.  In addition, each subject must be given a copy of the 
signed consent document. 
• All protocol amendments and changes to approved research must be submitted to the 
IRB and not be implemented until approved by the IRB except where necessary to 
eliminate apparent immediate hazards to the study subjects. 
• Significant changes to the study site and significant deviations from the research protocol 
must be reported. 
Please contact the Avera Dept of Human Subjects Protection (DHSP) at (605) 322-
4706 if you have any questions about the terms of this approval. 
 
Sincerely yours, 
 
Sandra G.  Ellenbolt, CIM, JD 
Director, Department of Human Subjects Protection/IRB Chair 
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APPENDIX D 
AMG University Psychiatry associates 
4400 W. 69th Street Sioux Falls SD 
57108 
 
Dear Dr. Stanley: 
 
Regarding Our Study # 2014.081 
Protocol Title: Pharmacogenetic testing in an outpatient population of patients 
with Major Depressive Disorder or Depressive Disorder not otherwise 
specified with Avera University Psychiatry Associates 
 
This is to inform you that on behalf of the Avera IRB I have reviewed your request regarding 
the above referenced research study. This request qualified for expedited review under FDA 
and NIH (OHRP) regulations.  This is to confirm that on behalf of the Avera IRB I have 
approved your request. 
 
Our Internal Number: 7678 
The following items were reviewed and approved: 
• UPA Protocol Amendment 1 1.23.15 
• UPA PGx Patient invitation letter Amend 1, 1.23.15 
• UPA PGx Schedule of Participation Amend, 1.23.15 
• UPA Patient Packet letter Amend 1, 1.23.15 
• UPA Questionnaire packet letter Amend 1, 1.23.15 
• FIBSER questionnaire 
• Beck Depression Inventory II 
• Telephone consent Script 
The requested changes to the protocol have been approved. 
 
The study is subject to continuing review on or before 1/21/2016. You are reminded that you 
are required to report any serious adverse events to the Avera Institutional Review Board within 
ten (10) business days of its occurrence (or your knowledge thereof). 
 
Please note that changes to the study as approved must be promptly reported and approved. 
Some changes may be approved by expedited review; others require full Board review. Contact 
the Avera Institutional Review Board, at (605) 322-4755, if you have any questions or require 
further information regarding this IRB action. 
 
Respectfully yours, 
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APPENDIX E 
Supporting documents for Informed Consent 
AVERA HEALTH PLAN- PGX TIME                                                                                                                                   
 PSYCHOTROPIC GENOTYPING PANEL RESEARCH STUDY 
SCHEDULE OF PARTICIPATION 
  
Screening 
Stabilization 
Visit 1 
visit 1A 
(letter/p
hone 
contact) 
Visit 2 Visit 3 Visit 4 Visit 5 
  
3 months or 
longer 
Day 0 Month 1 
Month 
2 
Month 
3 
Month 
6 
Month 
12 
Procedure        
Enter Care Coordination x       
Informed consent for the 
PGX study 
x*1 x*1 x*1 x*1 x*1 x*1 x*1 
Current medications x x x x x x x  
Medical history x       
Demographics x       
Adverse Events  x  x x x x 
Questionnaires  x  x x x x 
Pharmacogenetic testing        
PGx testing (blood 
drawn and sent to 
AIHG) 
 x      
PGX recommended 
changes begin 
 
 
 
 
x 
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*1. Informed consent may be completed on or before day 0, and is an ongoing process throughout the study.  
*4. Short-Form-12, Quality of Life measurement 
*5 STARD-Patient rated Inventory of Side Effects. 
APPENDIX E 
 
The Patient Health Questionnaire-9 (PHQ-9)  is 9 questions and will ask you about your depression. It is used to help your care providers 
understand the severity of your depression. 
The Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR) is a 16 item questionnaire which assesses for symptoms related to 
common symptoms experienced in depression. 
The Short Form-36 (SF-36) health outcomes measure is 36 questions in length and addresses physical, social and emotional aspects about your 
health.  
The STAR*D-Patient rated Inventory of Side Effects (STAR*D-PRISE) is 20 questions and will ask you about any side effects that may be related to 
taking antidepressant medications. 
 
Frequency, Intensity and Burden of Side Effects (FIBSER) scale asks 3 questions about the frequency, intensity and burden of your side effects. 
 
The following two Questionnaires will be taken by 100 participants at two time points (Day 0) and Month 3: 
 
 
• Patient Activation Measure-Mental Health (PAM-MH) is a 13 item questionnaire which asks you about your confidence level and 
knowledge about your health care.  
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APPENDIX E 
Supporting documents for Informed Consent 
Avera Institute for Human Genetics 
Protecting Your Rights and Privacy as a Research Participant 
 
Your privacy is very important to us. Like any other clinic or hospital visit, we are required to keep 
your personal and medical information confidential before, during, and after your visit. 
 
Our dedication to privacy extends beyond our doctors and nurses to include everyone employed 
in our healthcare family. We want you to feel safe knowing your personal and medical information 
is protected throughout Avera McKennan’s entire healthcare system. 
 
How will my personal information be protected? 
Information collected for research studies is confidential. Data collected and the specimen bank 
are the property of the Avera Institute for Human Genetics. In the event of any publication 
regarding this study, your identity will not be disclosed. 
 
Employees of the Avera Institute for Human Genetics and the Avera Institutional Review Board 
(IRB) may see parts of your medical records related to your participation in a study. The Avera IRB 
is a group of scientific and non-scientific individuals that helps protect the safety and welfare of 
subjects in research studies. 
 
We will make every effort to protect your privacy. Here are just a few of the steps we will take: 
• We will keep your data coded and secure to ensure that your sample(s) and information 
remain anonymous and can be used for quality research. 
• We will remove your name and other identifiers from your sample(s) and information, and 
replace them with a code number. We will keep the list that links the code number to your 
name separate from your sample(s) and information. Only a few of the researchers will have 
access to the list and they sign an agreement to keep your identity a secret. 
• Avera safety monitors or committees, as well as the Avera IRB, may have access to your 
records, but only in their role of ensuring the study is being done safely and correctly. 
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• Researchers who study your sample(s) and information will not know who you are. 
Disciplinary actions, including termination of employment, may result if an employee tries 
to determine your identity. 
• We will not give information that identifies you to anyone, except if required by law. 
Information that is shared outside of the Avera Institute for Human Genetics may no longer 
be protected by the federal privacy law called “HIPAA”; however, it will be protected as 
described in this form and may be covered by other privacy laws. 
• The results of a study could be presented at a scientific meeting or published in an article, 
but would be presented as a general analysis of many study donations and would not 
include any information that would let others know who you are or any other study 
participants are. 
 
Who can see or use my information?  
Signing a study’s informed consent document gives the researchers your permission to obtain, 
use, and share information about you for the study, and is required in order for you to take part 
in the study. Information about you may be obtained from any hospital, doctor, and other health 
care provider involved in your care. 
 
Information about you may include information about your health and your medical care before, 
during, and after the study, even if that information wasn’t collected as part of the research study. 
For example: 
• Hospital/doctor’s office records, including test results (X-rays, blood tests, urine tests, etc.) 
• Mental health care records (except psychotherapy notes not kept with your medical records 
• Alcohol/substance abuse treatment records 
• All records relating to your condition, the treatment you have received, and your response 
to the treatment 
• Billing information  
 
There are many reasons why information about you may be used or seen by the researchers or 
others during the study. Examples include the following: 
• The researchers may need the information to check your test results or look for side effects. 
• Avera Institute for Human Genetics and government officials may need the information to 
make sure that the study is done properly. 
• Organizations that are funding the study may need the information to make sure that the 
study is done properly. 
• The researchers may need to use the information to create a data bank of information 
about your condition or its treatment. 
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What happens to information about me after the study is over or if I cancel my permission? 
As a rule, the researchers will not continue to use or disclose information about you, but will keep 
it secure until is destroyed, Sometimes, it may be necessary for information about you to continue 
to be used or disclosed, even after you have canceled your permission or the study is over. 
Examples of reasons for this include the following: 
• To avoid losing study results that have already included your information. 
• To provide limited information for research, education, or other activities. (This information 
would not include your name, social security number, or anything else that could let others 
know who you are.) 
• To help the Avera Institute for Human Genetics and government officials make sure that 
the study was conducted properly. 
 
 
If you have questions about your rights in the study, you should contact: 
Avera Institutional Review Board 
3900 West Avera Drive 
Sioux Falls, SD 57108 
(605) 322-4755 
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Informed Consent for Psychotropic Genotyping Panel Research Study 
 
First name: ____________________________ Last name: 
______________________ 
DOB: __________________   Male   Female 
Test to be completed: ____Psychotropic Genotyping Panel_________ 
Purpose of the Study 
You are invited to volunteer to be in a research study to evaluate the effectiveness of determining 
the right medications based on your genetic profile. This genetics testing uses a blood sample to 
get a snap shot of how your liver will metabolize medications; it will not show risk for getting a 
disease. The primary objective of this study is to draw blood and find out which medications, 
based on your individual genetics, might work best in treating you. This type of testing is currently 
available as a service at Avera and other laboratories; however, we hope that this study will 
support and/or add to the use of this genetic testing in clinical practice. 
 
You have been identified by your physician as meeting criteria for this research study. This blood 
test is not a treatment; the genetic analysis, along with other information, will be considered by 
professionals to make clinical medication recommendations for your treatment. With your 
consent, your medical history, demographics, and list of medications will be accessed and utilized 
by research staff to make these recommendations to the providers involved in your care. This 
study will use questionnaires to measure the effectiveness in providing this genetic testing. 
 
Study Involvement 
If you consent to take part in this study, your physical involvement is limited to about 12 months 
and will include informed consent, collection of a blood sample, standard care clinic visits, and 
questionnaires taken about every 3 months over that time. You will need to visit an Avera 
Laboratory draw location to have your blood drawn. Lab staff will collect two purple-top EDTA 
tubes, with at least 2 ml (about ½ a teaspoon) in each tube. It may also be necessary for research 
staff to contact you regarding questionnaires or for other information needed for the conduct of 
the study. Your consent will also allow staff to access your medical records for the 12 months 
prior to your enrollment into this research study. Please refer to the Psychotropic Genotyping 
Panel Research Study Schedule of Participation for a more detailed explanation of procedures 
and questionnaires. Also, with your consent, your blood sample will be stored in the Avera 
Institute for Human Genetics (AIHG) Specimen Bank indefinitely for use in studying future genetic 
and genomic issues. Your sample will be coded in order to protect your identity in any future 
studies. 
 
Privacy and Confidentiality 
Your privacy is very important to us. We are required to keep your personal and medical 
information confidential before, during, and after your clinic visit. At all times, Avera has 
appropriate administrative, technical, and physical safeguards in place to protect the privacy of 
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your personal health information. Your genetic report will be entered into your Avera electronic 
medical record and will only be accessed by clinicians directly involved in your care and by 
designated research staff involved in this study. Your genetic report is confidential to the extent 
required by law and may only be released to other medical professionals with your written 
consent. We want you to feel safe knowing our personal and medical information is protected 
throughout Avera’s entire healthcare system. Our dedication to privacy extends beyond our 
doctors and nurses to include everyone employed in our healthcare family.  
 
Benefits and Risks of Participation 
This pharmacogenetic test only looks at how your body processes (or metabolizes) medications, 
providing clinicians with a tool for prescribing the safest and most effective medications, helping 
avoid adverse effects. Your doctor will receive a report that tells which medications may help best 
treat you. If you have "normal" metabolism, your doctor will prescribe medications based on 
current best practice standards, the same as if you do not have this test. 
Although the chance is small, there is a risk that someone could get access to the data 
confidentially stored about you. There is also the risk someone could trace the information in a 
scientific database back to you. Even without your name or other identifiers, genetic information is 
unique to you. The Genetic Information Nondiscrimination Act (GINA) generally protects you 
against discrimination based on your genetic information when it comes to health insurance and 
employment. Please refer to the AIHG Protecting Your Rights and Privacy as a Research 
Participant document for additional information on how your personal and medical information is 
protected.  
 
Discomforts associated with the blood draw may include brief pain, slight bleeding, or a bruise 
from the site. Rarely, a small blood clot or infection could originate from the site of the needle 
puncture. In the event of any physical injury resulting from research procedures, medical 
treatment will be provided without cost to you. If you have an illness or injury during this research 
study that is not directly related to your participation, you and/or your insurance will be 
responsible for the cost of the medical care of that illness or injury. 
 
There is no compensation for taking part in this research study. This study will pay for the cost of 
the blood draw and genetic testing. Any required study-related visits outside of standard of care 
for your treatment may be covered under this research. Ask the study staff if you have any 
questions about bills, fees or other costs related to this study. 
 
Voluntary Participation and Withdrawing Participation 
Your participation in this study is voluntary. You may refuse to participate, or may stop 
participation at any time, even after signing this document, without a penalty or loss of benefits to 
which you are otherwise entitled now and in the future. Your participation may also be stopped by 
the study physician without your consent, if he/she feels that is best for you. If you choose to stop 
your participation, the researchers will destroy any remaining blood sample and will stop using or 
disclosing information about you. Sometimes, however, it may be necessary for information about 
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you to continue to be used or disclosed, even after you have canceled your permission or the 
study has ended. An example of this would be to show auditing authorities that the study was 
conducted properly. 
 
Volunteer’s Statement  
When you sign this form, you are agreeing to take part in this research study. This means that 
you have read the consent form, your questions have been answered, and you have decided to 
volunteer. Do not sign this consent form unless you have had a chance to ask questions, and 
have received satisfactory answers to all of your questions. If you have additional questions about 
taking part in this study, would like to withdraw, or have a research-related injury, you may 
contact the Avera Institute for Human Genetics at (605) 322-3050. If you have questions about 
your rights as a research participant, call the Avera Department of Human Subjects Protection at 
(605) 322-4706. 
 
□  Yes, I want to donate any remaining blood sample to the AIHG Specimen Bank. Checking 
this box provides my consent to have my stored blood sample to be used for future research, 
as well as for access to my Avera electronic medical record, if needed. I understand I may 
withdraw this consent at any time by calling AIHG at (605) 322-3050. 
□    No, I do not want to donate any remaining blood sample to the AIHG Specimen Bank. 
 
I have read and understand the above information. I understand taking part in this 
research study is voluntary. I understand I may quit the study at any time without harming 
future medical care or losing any benefits to which you might otherwise be entitled. I have 
received the AIHG Protecting Your Rights and Privacy as a Research Participant and 
Pharmacogenetic Research Schedule of Participation documents. I will be given a copy of 
this signed document by requesting a copy by calling the phone number listed below. By 
signing below, I am agreeing to take part in this study. 
 
 
________________________  _____________________________  ___________________ 
Name of Patient (Print)    Signature     Date (day, 
month, year)  
 
_________  _____________________________  ___________________ Name of 
Person Obtaining   Signature     Date (day, month, year) 
Consent (Print)  
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Appendix F 
Patient Invitation Letter 
Dear Avera Care Coordination Patient: 
 
As a patient in the Avera Care Coordination program, you have been 
identified as being eligible to participate in a research study for a blood test 
that can assist your physician in improving your care through medication 
management. The test would be available to you at no cost.  
 
Rather than taking a medication and waiting to see if it works, this test 
provides information on how your body will process and use medications, as 
well as how the medications you currently take interact with each other. 
Recommendations can then be made to your care team as to what 
medications may work best for you.  
 
In order to enroll in this study, you will need to do the following:  
 
 Read and sign an Informed Consent Document. This document 
explains what your participation would include, any risks and benefits, 
and other information you may want to consider before participating in 
the study.  
DO NOT sign this document until you have had an opportunity to 
speak to staff about it. 
 
 Have your blood drawn at an Avera McKennan or other Avera 
facility laboratory. If you meet eligibility criteria and sign the Informed 
Consent Document, study staff will deliver a Genotyping Panel 
laboratory requisition to an Avera location of your choosing for the blood 
draw. 
 
 Answer a few questions on your past and present experiences with 
medications. This information may help the research staff make 
additional correlations between genetics and medication responses. 
 
If you do not receive a letter and information from the Avera Institute for 
Human Genetics in the next few days regarding this opportunity and 
would like to participate, please call (605) 322-3050 for more 
information or to see if you are eligib
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APPENDIX G 
 
December 18, 2015 Matthew Stanley, D.O. 
AMG University Psychiatry associates 4400 W. 69th Street 
Sioux Falls SD 57108 
 
RE:  Our Study #2014.080 
Dear Dr. Stanley: 
Meeting Date: 12/17/2015 
Protocol Title: Title: Pharmacogenetic testing in an outpatient population of patients with 
Major Depressive Disorder or Depressive Disorder Not Otherwise Specified with Avera 
Medical Group Clinics 
 
This is to inform you the Avera IRB renewed its approval of the above research study. The 
renewal is granted for an additional 12 months. 
 
The Effective date of the renewal is 12/17/2015: The approval period will expire on 
12/16/2016 
Our internal number: 8185 
The following items were reviewed: 
• Continuing Review Report dated 3-Dec-2015 
• Informed Consent dated 23-Jan-2015 
 
All conditions for continued approval during the prior approval period remain in 
effect. These include, but are not necessarily limited to the following requirements: 
• A stamped copy of the most current Informed Consent Document (as noted 
above) is included. No other consent documents should be used. Each subject must 
sign the approved ICD prior to initiation of any protocol procedures. The original 
signed informed consent document must be placed in each subject’s 
medical/research chart.  In addition, each subject must be given a copy of the 
signed consent document. 
• All protocol amendments and changes to approved research must be submitted to the 
IRB and not be implemented until approved by the IRB except where necessary to 
eliminate apparent immediate hazards to the study subjects. 
Please contact the Avera Dept of Human Subjects Protection (DHSP) at (605) 322-
4706 if you have any questions about the terms of this approval. 
 
 
Sincerely yours, 
 
Sandra G.  Ellenbolt, CIM, JD 
Director, Department of Human Subjects Protection/IRB Chair 
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APPENDIX H 
 
Table 33 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Allele variation:  CYP 2D6 genotype 
                               Allele Frequency Percent 
 *1 3 2.4 
*1/*1 14 11.3 
*1/*10 3 2.4 
*1/*2 28 22.6 
*1/*4 10 8.1 
*1/*41 13 10.5 
*1/*6 1 .8 
*1/*9 1 .8 
*10 1 .8 
*10/*41 2 1.6 
*2 3 2.4 
*2/*2 6 4.8 
*2/*4 9 7.3 
*2/*41 7 5.6 
*2/*6 1 .8 
*2/*9 2 1.6 
*4/*4 5 4.0 
*4/*41 3 2.4 
*4/*9 2 1.6 
*41 2 1.6 
*41/*41 2 1.6 
Total 118 95.2 
136 
  
 
 
 
Table 34 
 
Allele variation CYP2C9gene 
                Allele Frequency Percent 
 *1/*1 70 56.5 
*1/*12 1 .8 
*1/*2 29 23.4 
*1/*23 1 .8 
*1/*3 13 10.5 
*2/*2 3 2.4 
Total 117 94.4 
Missing 666 7 5.6 
Total 124 100.0 
 
  Table 35 
 
Allele variation CYP3A4gene 
                 Allele Frequency Percent 
 *1*1 1 .8 
*1/*1 104 83.9 
*1/*1,1/*10, *10/*10 1 .8 
*1/*22 10 8.1 
*3/*11 1 .8 
Total 117 94.4 
Missing 666 7 5.6 
Total 124 100.0 
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Table 36 
Allele variation CYP2C19gene 
                 Allele Frequency Percent 
 *1/*1 48 38.7 
*1/*17 33 26.6 
*1/*2 2 1.6 
*1/*2A 15 12.1 
*1/*2B 1 .8 
*1/*8 1 .8 
*17/*17 6 4.8 
*2A/*17 7 5.6 
*2A/*2A 2 1.6 
*2B/*17 2 1.6 
Total 117 94.4 
Missing 666 7 5.6 
Total 124 100.0 
 
 Table 37 
 
Allele variation CYP1A2gene 
              Allele Frequency Percent 
 *1A/*1A 14 11.3 
*1A/*1F 41 33.1 
*1B/*1B 1 .8 
*1B/*1F 1 .8 
*1B/*1L 1 .8 
*1B/*1P 1 .8 
*1f/*1F 1 .8 
*1F/*1F 54 43.5 
*1F/*1K 1 .8 
*1L/*1L 1 .8 
1F/*1L 1 .8 
Total 117 94.4 
Missing 666 7 5.6 
Total 124 100.0 
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 Table 38 
Allele variation CYP2B6gene 
                 Allele Frequency Percent 
 *1/*1 33 26.6 
*1/*11 1 .8 
*1/*15 2 1.6 
*1/*2 7 5.6 
*1/*22 1 .8 
*1/*5 21 16.9 
*1/*6 29 23.4 
*1/*7 or 
*5/*6 
1 .8 
*1/*7, *5/*6 1 .8 
*1/*7,*5/*6 2 1.6 
*1/*7,*5/*69 1 .8 
*1/7, *5/*6 1 .8 
*2/*5 1 .8 
*2/*6 4 3.2 
*4/*5 1 .8 
*5/*5 1 .8 
*5/*6 1 .8 
*6/*14 1 .8 
*6/*15 1 .8 
*6/*6 7 5.6 
Total 117 94.4 
Missing 666 7 5.6 
Total 124 100.0 
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